Announcement

Collapse
No announcement yet.

US FluView - Weekly Surveillance Flu report 2024/2025 season - for trend analysis

Collapse
This is a sticky topic.
X
X
 
  • Filter
  • Time
  • Show
Clear All
new posts

  • #31
    Weekly US Influenza Surveillance Report: Key Updates for Week 23, ending June 7, 2025

    For Everyone
    June 13, 2025

    Key points


    Seasonal influenza activity is low.
    U.S. virologic surveillance

    Clinical Laboratories


    The results of tests performed by clinical laboratories nationwide are summarized below. Data from clinical laboratories (the percentage of specimens tested that are positive for influenza) are used to monitor whether influenza activity is increasing or decreasing. Nationally, during Week 23, the percentage of respiratory specimens testing positive for influenza virus in clinical laboratories was 1.7%.
    No. of specimens tested 32,752 3,513,159
    No. of positive specimens (%) 564 (1.7%) 486,440 (13.8%)
    Positive specimens by type
    Influenza A 198 (35.1%) 433,160 (89.0%)
    Influenza B 366 (64.9%) 53,280 (11.0%)
    Public Health Laboratories


    The results of tests performed by public health laboratories nationwide are summarized below. Data from public health laboratories are used to monitor the proportion of circulating viruses that belong to each influenza virus type/subtype/lineage. Viruses known to be associated with recent live attenuated influenza vaccine (LAIV) receipt or found upon further testing to be a vaccine virus are not included as they are not circulating influenza viruses.
    No. of specimens tested 495 146,540
    No. of positive specimens 60 98,208
    Positive specimens by type/subtype
    Influenza A 31 (51.7%) 92,670 (94.4%)
    Subtyping Performed 24 (77.4%) 83,015 (89.6%)
    (H1N1)pdm09 21 (87.5%) 43,751 (52.7%)
    H3N2 3 (12.5%) 39,185 (47.2%)
    H3N2v 0 0
    H5 0 79 (0.1%)
    Subtyping not performed 7 (22.6%) 9,655 (10.4%)
    Influenza B 29 (48.3%) 5,538 (5.6%)
    Lineage testing performed 18 (62.1%) 3,078 (55.6%)
    Yamagata lineage 0 0
    Victoria lineage 18 (100%) 3,078 (100%)
    Lineage not performed 11 (37.9%) 2,460 (44.4%)
    Additional virologic surveillance information for current and past seasons:

    Surveillance Methods | FluView Interactive: National, Regional, and State Data or Age Data

    Novel Influenza A Virus Infections


    No confirmed human infections with influenza A(H5) virus were reported to CDC this week. To date, human-to-human transmission of avian influenza A(H5) virus (H5 bird flu) has not been identified in the United States.

    The CSTE position statement, which includes updated case definitions for confirmed, probable, and suspected cases is available at http://www.cste.org/resource/resmgr/...nfluenza_A.pdf

    An up-to-date human case summary during the current outbreak by state and exposure source is available at www.cdc.gov/bird-flu/situation-summary/index.html

    Information about avian influenza is available at https://www.cdc.gov/flu/avianflu/index.htm.

    A(H5N1) virus interim recommendations for Prevention, Monitoring, and Public Health Investigations are available at https://www.cdc.gov/bird-flu/prevent...endations.html.

    The latest case reports on avian influenza outbreaks in wild birds, commercial poultry, backyard or hobbyist flocks, and mammals in the United States are available from the USDA at https://www.aphis.usda.gov/h5n1-hpai#detections-hpai.

    Additional information regarding human infections with novel influenza A viruses:

    Surveillance Methods | FluView Interactive
    Outpatient and Emergency Department Illness Surveillance

    Outpatient respiratory illness visits


    The U.S. Outpatient Influenza-like Illness Surveillance Network (ILINet) monitors outpatient visits for respiratory illness referred to as influenza-like illness [ILI (fever plus cough or sore throat)], not laboratory-confirmed influenza, and may capture respiratory illness visits due to infection with any pathogen that can present with similar symptoms, including influenza, SARS-CoV-2, and RSV. Therefore, it is important to evaluate syndromic surveillance data, including that from ILINet, in the context of other sources of surveillance data to obtain a complete and accurate picture of influenza, SARS-CoV-2, and other respiratory virus activity.

    Nationwide during Week 23, 1.6% of patient visits reported through ILINet were due to respiratory illness that included fever plus a cough or sore throat, also referred to as ILI. Multiple respiratory viruses are co-circulating, and the relative contribution of influenza virus infection to ILI varies by location.

    Outpatient respiratory illness visits by age group


    More than 70% of ILINet participants provide both the number of patient visits for respiratory illness and the total number of patient visits for the week broken out by age group. Data from this subset of providers are used to calculate the percentages of patient visits for respiratory illness by age group.

    During Week 23, the percentage of visits for respiratory illness reported in ILINet was 5.4% among those 0-4 years, 2.2% among those 5-24 years, 1.3% among those 25-49 years, 0.9% among those 50-64 years, and 0.7% among those 65 years and older.

    Outpatient respiratory illness activity map


    Data collected in ILINet are used to produce a measure of ILI activity* by state/jurisdiction and Core Based Statistical Areas (CBSA).
    Week 23
    (Week ending
    Jun. 7, 2025)
    Week 22
    (Week ending
    May 31, 2025)
    Week 23
    (Week ending
    Jun. 7, 2025)
    Week 22
    (Week ending
    May 31, 2025)
    Very High 0 0 0 0
    High 0 0 0 1
    Moderate 0 0 2 2
    Low 0 2 6 17
    Minimal 53 53 666 674
    Insufficient Data 2 0 255 235

    *Data collected in ILINet may disproportionally represent certain populations within a jurisdiction or CBSA, and therefore, may not accurately depict the full picture of influenza activity for the entire jurisdiction or CBSA. Differences in the data presented here by CDC and independently by some health departments likely represent differing levels of data completeness with data presented by the health department likely being the more complete.

    Additional information about medically attended visits for ILI for current and past seasons:

    Surveillance Methods | FluView Interactive: National, Regional, and State Data or ILI Activity Map

    National Syndromic Surveillance System (NSSP)


    The overall percentage of emergency department (ED) visits with a discharge diagnosis of influenza reported in NSSP was 0.2% during Week 23. The percentage of visits was 0.5% among those 0-4 years, 0.5% among those 5-17 years, 0.2% among those 18-64 years, and 0.1% among those 65 years and older. RegionNationalRegion 1Region 2Region 3Region 4Region 5Region 6Region 7Region 8Region 9Region 10
    Season2023-2024 & 2024-20252022-2023 Skip Over Chart Container
    2.0%4.0%6.0%8.0%10.0%12.0%14.0%16.0%Percent of Emergency Department Visits for InfluenzaWeek 43 of 2023Week 47 of 2023Week 51 of 2023Week 3 of 2024Week 7 of 2024Week 11 of 2024Week 15 of 2024Week 19 of 2024Week 23 of 2024Week 27 of 2024Week 31 of 2024Week 35 of 2024Week 39 of 2024Week 43 of 2024Week 47 of 2024Week 51 of 2024Week 3 of 2025Week 7 of 2025Week 11 of 2025Week 15 of 2025Week 19 of 2025Week 23 of 2025

    Age Group


    All ages
    0-4 years
    5-17 years
    18-64 years
    65+ Skip Data Table
    Data Table Download Data (CSV) Skipped data table.

    Additional information about emergency department visits for flu for current and past seasons:‎‎‎

    Surveillance Methods | Emergency Department Visits for COVID-19, flu, and RSV
    Hospitalization surveillance

    FluSurv-Net


    The Influenza Hospitalization Surveillance Network (FluSurv-NET) conducts population-based surveillance for laboratory-confirmed influenza-related hospitalizations in select counties in 14 states and represents approximately 9% of the U.S. population. FluSurv-NET hospitalization data are preliminary. Patients admitted for laboratory-confirmed influenza-related hospitalization after April 30, 2025, will not be included in FluSurv-NET for the 2024-2025 season. Data on patients admitted through April 30, 2025, will continue to be updated on FluView Interactive as additional information is received.

    Additional FluSurv-NET hospitalization surveillance information for current and past seasons and additional age groups:

    Surveillance Methods | FluView Interactive: Rates by Age, Sex, and Race/Ethnicity or Data on Patient Characteristics | RESP-NET Interactive

    National Healthcare Safety Network (NHSN) Hospital Respiratory Data


    Hospitals report to NHSN the weekly number of patients with laboratory-confirmed influenza who were admitted to the hospital. Nationally, during Week 23, 1,455 (0.4 per 100,000 population) laboratory-confirmed influenza-associated hospitalizations were reported. When examining rates by age, the highest hospital admission rate per 100,000 population was among those 65 years and older (1.2), followed by those 0-4 years (0.5), and the 50-64 years age group (0.4).

    Additional NHSN Hospital Respiratory Data information:

    Surveillance Methods | Additional Data | FluView Interactive
    Mortality surveillance

    National Center for Health Statistics (NCHS) Mortality Surveillance


    Based on NCHS mortality surveillance data available on June 12, 2025, 0.1% of the deaths that occurred during the week ending June 7, 2025 (Week 23) were due to influenza. The data presented are preliminary and may change as more data are received and processed.



    View Chart Data

    Additional pneumonia, influenza and COVID-19 mortality surveillance information for current and past seasons:

    Surveillance Methods | FluView Interactive

    Influenza-Associated Pediatric Mortality


    Five influenza-associated pediatric deaths occurring during the 2024-2025 season were reported to CDC during Week 23. The deaths occurred between weeks 5 and 17 (the weeks ending February 1, 2025, and April 26, 2025, respectively). A total of 246 influenza-associated pediatric deaths occurring during the 2024-2025 season have been reported to CDC. This is the highest number of pediatric deaths reported in any non-pandemic influenza season since the condition became reportable in 2004.

    Among children who were eligible for influenza vaccination and with known vaccine status, 90% of reported pediatric deaths this season (compared to 82% during the 2023-2024 season) have occurred in children who were not fully vaccinated against influenza.

    Additional pediatric mortality surveillance information for current and past seasons:

    Surveillance Methods | FluView Interactive
    Additional National and International Influenza Surveillance Information

    Additional surveillance information


    FluView Interactive: FluView includes enhanced web-based interactive applications that can provide dynamic visuals of the influenza data collected and analyzed by CDC. These FluView Interactive applications allow people to create customized, visual interpretations of influenza data, as well as make comparisons across flu seasons, regions, age groups and a variety of other demographics.

    National Institute for Occupational Safety and Health: Monthly surveillance data on the prevalence of health-related workplace absenteeism among full-time workers in the United States are available from NIOSH.

    Comment


    • #32
      Weekly US Influenza Surveillance Report: Key Updates for Week 27, ending July 5, 2025

      For Everyone
      July 11, 2025

      Key points


      Seasonal influenza activity is low.
      U.S. virologic surveillance

      Clinical Laboratories


      The results of tests performed by clinical laboratories nationwide are summarized below. Data from clinical laboratories (the percentage of specimens tested that are positive for influenza) are used to monitor whether influenza activity is increasing or decreasing. Nationally, during Week 27, the percentage of respiratory specimens testing positive for influenza virus in clinical laboratories was 0.9%.
      No. of specimens tested 23,905 3,666,248
      No. of positive specimens (%) 206 (0.9%) 488,112 (13.3%)
      Positive specimens by type
      Influenza A 120 (58.3%) 433,970 (88.9%)
      Influenza B 86 (41.7%) 54,142 (11.1%)

      Public Health Laboratories


      The results of tests performed by public health laboratories nationwide are summarized below. Data from public health laboratories are used to monitor the proportion of circulating viruses that belong to each influenza virus type/subtype/lineage. Viruses known to be associated with recent live attenuated influenza vaccine (LAIV) receipt or found upon further testing to be a vaccine virus are not included as they are not circulating influenza viruses.
      No. of specimens tested 280 149,206
      No. of positive specimens 26 99,020
      Positive specimens by type/subtype
      Influenza A 24 (92.3%) 93,248 (94.2%)
      Subtyping Performed 17 (70.8%) 83,646 (89.7%)
      (H1N1)pdm09 16 (94.1%) 44,183 (52.8%)
      H3N2 1 (5.9%) 39,384 (47.1%)
      H3N2v 0 0
      H5* 0 79 (0.1%)
      Subtyping not performed 7 (29.2%) 9,602 (10.3%)
      Influenza B 2 (7.7%) 5,772 (5.8%)
      Lineage testing performed 0 3,218 (55.8%)
      Yamagata lineage 0 0
      Victoria lineage 0 3,218 (100%)
      Lineage not performed 2 (100%) 2,554 (44.2%)
      *These data reflect specimens tested, and the number determined to be positive for influenza viruses at the public health labs (specimens tested is not the same as cases). The data do not reflect specimens tested only at CDC and could include more than one specimen tested per person. The guidance for avian influenza A(H5) virus testing recommends testing both a conjunctival and respiratory swab for people with conjunctivitis which has resulted in more specimens testing positive for avian influenza A(H5) virus than the number of human A(H5) cases. For more information on the number of people infected with avian influenza A(H5) viruses, please visit the "How CDC is monitoring influenza data among people to better understand the current avian influenza A (H5N1) situation"

      When an influenza virus that normally circulates in swine (but not people) is detected in a person, it is called a "variant" influenza virus. Most human infections with variant influenza viruses occur following exposure to swine, but human-to-human transmission can occur. It is important to note that in most cases, variant influenza viruses have not shown the ability to spread easily and sustainably from human-to-human.



      *This graph reflects the number of specimens tested and the number determined to be positive for influenza viruses at the public health lab (specimens tested is not the same as cases). It does not reflect specimens tested only at CDC and could include more than one specimen tested per person. Specimens tested as part of routine influenza surveillance as well as those tested as part of targeted testing for people exposed to avian influenza A(H5) are included.

      Additional virologic surveillance information for current and past seasons:

      Surveillance Methods | FluView Interactive: National, Regional, and State Data or Age Data

      Novel Influenza A Virus Infections


      No confirmed human infections with influenza A(H5) virus were reported to CDC this week. To date, human-to-human transmission of avian influenza A(H5) virus (H5 bird flu) has not been identified in the United States.

      The CSTE position statement, which includes updated case definitions for confirmed, probable, and suspected cases is available at http://www.cste.org/resource/resmgr/...nfluenza_A.pdf.

      An up-to-date human case summary during the current outbreak by state and exposure source is available at www.cdc.gov/bird-flu/situation-summary/index.html.

      Information about avian influenza is available at https://www.cdc.gov/flu/avianflu/index.htm.

      A(H5N1) virus interim recommendations for Prevention, Monitoring, and Public Health Investigations are available at https://www.cdc.gov/bird-flu/prevent...endations.html.

      The latest case reports on avian influenza outbreaks in wild birds, commercial poultry, backyard or hobbyist flocks, and mammals in the United States are available from the USDA at https://www.aphis.usda.gov/h5n1-hpai#detections-hpai.

      Additional information regarding human infections with novel influenza A viruses:

      Surveillance Methods | FluView Interactive
      Outpatient and Emergency Department Illness Surveillance

      Outpatient Respiratory Illness Visits


      The U.S. Outpatient Influenza-like Illness Surveillance Network (ILINet) monitors outpatient visits for respiratory illness referred to as influenza-like illness [ILI (fever plus cough or sore throat)], not laboratory-confirmed influenza, and may capture respiratory illness visits due to infection with any pathogen that can present with similar symptoms, including influenza, SARS-CoV-2, and RSV. Therefore, it is important to evaluate syndromic surveillance data, including that from ILINet, in the context of other sources of surveillance data to obtain a complete and accurate picture of influenza, SARS-CoV-2, and other respiratory virus activity.

      Nationally, during Week 27, 1.1% of patient visits reported through ILINet were due to respiratory illness that included fever plus a cough or sore throat, also referred to as ILI. Multiple respiratory viruses are co-circulating, and the relative contribution of influenza virus infection to ILI varies by location.

      Outpatient Respiratory Illness Visits by Age Group


      More than 70% of ILINet participants provide both the number of patient visits for respiratory illness and the total number of patient visits for the week broken out by age group. Data from this subset of providers are used to calculate the percentages of patient visits for respiratory illness by age group.

      During Week 27, the percentage of visits for respiratory illness reported in ILINet was 3.6% among those 0-4 years, 1.4% among those 5-24 years, 0.9% among those 25-49 years, 0.7% among those 50-64 years, and 0.6% among those 65 years and older.

      Outpatient Respiratory Illness Activity Map


      Data collected in ILINet are used to produce a measure of ILI activity* by state/jurisdiction and Core Based Statistical Areas (CBSA).
      Week 27
      (Week ending
      Jul. 5, 2025)
      Week 26
      (Week ending
      Jun. 28, 2025)
      Week 27
      (Week ending
      Jul. 5, 2025)
      Week 26
      (Week ending
      Jun. 28, 2025)
      Very High 0 0 0 0
      High 0 0 0 0
      Moderate 0 0 0 0
      Low 0 0 1 0
      Minimal 55 55 693 693
      Insufficient Data 0 0 235 236

      *Data collected in ILINet may disproportionally represent certain populations within a jurisdiction or CBSA, and therefore, may not accurately depict the full picture of influenza activity for the entire jurisdiction or CBSA. Differences in the data presented here by CDC and independently by some health departments likely represent differing levels of data completeness with data presented by the health department likely being the more complete.

      Additional information about medically attended visits for ILI for current and past seasons:

      Surveillance Methods | FluView Interactive: National, Regional, and State Data or ILI Activity Map

      National Syndromic Surveillance System (NSSP)


      The overall percentage of emergency department (ED) visits with a discharge diagnosis of influenza reported in NSSP was 0.1% during Week 27. The percentage of visits was 0.3% among those 0-4 years, 0.2% among those 5-17 years, 0.1% among those 18-64 years, and 0.1% among those 65 years and older. RegionNationalRegion 1Region 2Region 3Region 4Region 5Region 6Region 7Region 8Region 9Region 10
      Season2023-2024 & 2024-20252022-2023 Skip Over Chart Container
      2.0%4.0%6.0%8.0%10.0%12.0%14.0%16.0%Percent of Emergency Department Visits for InfluenzaWeek 43 of 2023Week 47 of 2023Week 51 of 2023Week 3 of 2024Week 7 of 2024Week 11 of 2024Week 15 of 2024Week 19 of 2024Week 23 of 2024Week 27 of 2024Week 31 of 2024Week 35 of 2024Week 39 of 2024Week 43 of 2024Week 47 of 2024Week 51 of 2024Week 3 of 2025Week 7 of 2025Week 11 of 2025Week 15 of 2025Week 19 of 2025Week 23 of 2025Week 27 of 2025

      Age Group

      Skip Data Table
      Data Table Download Data (CSV) Skipped data table.

      Additional information about emergency department visits for flu for current and past seasons:‎‎‎

      Surveillance Methods | Emergency Department Visits for COVID-19, flu, and RSV
      Hospitalization Surveillance

      FluSurv-Net


      The Influenza Hospitalization Surveillance Network (FluSurv-NET) conducts population-based surveillance for laboratory-confirmed influenza-related hospitalizations in select counties in 14 states and represents approximately 9% of the U.S. population. FluSurv-NET hospitalization data are preliminary. Patients admitted for laboratory-confirmed influenza-related hospitalization after April 30, 2025, will not be included in FluSurv-NET for the 2024-2025 season. Data on patients admitted through April 30, 2025, will continue to be updated on FluView Interactive as additional information is received.

      Additional FluSurv-NET hospitalization surveillance information for current and past seasons and additional age groups:

      Surveillance Methods | FluView Interactive: Rates by Age, Sex, and Race/Ethnicity or Data on Patient Characteristics | RESP-NET Interactive

      National Healthcare Safety Network (NHSN) Hospital Respiratory Data


      Hospitals report to NHSN the weekly number of patients with laboratory-confirmed influenza who were admitted to the hospital. Nationally, during Week 27, 911 (0.3 per 100,000 population) laboratory-confirmed influenza-associated hospitalizations were reported. When examining rates by age, the highest hospital admission rate per 100,000 population was among those 65 years and older (0.9), followed by those 0-4 years (0.3), and the 50-64 years age group (0.3).

      Additional NHSN Hospital Respiratory Data information:

      Surveillance Methods | Additional Data | FluView Interactive
      Mortality Surveillance

      National Center for Health Statistics (NCHS) Mortality Surveillance


      Based on NCHS mortality surveillance data available on July 10, 2025, 0.04% of the deaths that occurred during the week ending July 5, 2025 (Week 27) were due to influenza. The data presented are preliminary and may change as more data are received and processed.

      Additional pneumonia, influenza and COVID-19 mortality surveillance information for current and past seasons:

      Surveillance Methods | FluView Interactive

      Influenza-Associated Pediatric Mortality


      Four influenza-associated pediatric deaths occurring during the 2024-2025 season were reported to CDC during Week 27. The deaths occurred during weeks 9, 11, 21 and 24 (the weeks ending March 1, March 15, May 24, and June 14, 2025, respectively). A total of 260 influenza-associated pediatric deaths occurring during the 2024-2025 season have been reported to CDC. This is the highest number of pediatric deaths reported in any non-pandemic influenza season since the condition became reportable in 2004.

      Among children who were eligible for influenza vaccination and with known vaccine status, 89% of reported pediatric deaths this season (compared to 82% during the 2023-2024 season) have occurred in children who were not fully vaccinated against influenza.

      Additional pediatric mortality surveillance information for current and past seasons:

      Surveillance Methods | FluView Interactive
      All data in this report are preliminary and may change as more reports are received.

      A description of the CDC influenza surveillance system, including methodology and detailed descriptions of each data component, is available on the surveillance methods page.1

      Additional information on the current and previous influenza seasons for each surveillance component are available on FluView Interactive.

      Additional National and International Influenza Surveillance Information

      Additional surveillance information


      FluView Interactive: FluView includes enhanced web-based interactive applications that can provide dynamic visuals of the influenza data collected and analyzed by CDC. These FluView Interactive applications allow people to create customized, visual interpretations of influenza data, as well as make comparisons across flu seasons, regions, age groups and a variety of other demographics.

      National Institute for Occupational Safety and Health: Monthly surveillance data on the prevalence of health-related workplace absenteeism among full-time workers in the United States are available from NIOSH.

      Comment


      • #33
        Helen Branswell
        @HelenBranswell

        2h
        1. New pediatric #flu deaths for 2024-25 continue to be reported to #CDC; last week 4 more were added. The latest occurred in mid-June. There've been a staggering 260 deaths in '24-25, the worst year (except the 2009 pandemic) since CDC started tracking peds flu deaths. https://cdc.gov/fluview/surveillance/2025-week-27.html

        Comment


        • #34
          Weekly US Influenza Surveillance Report: Key Updates for Week 28, ending July 12, 2025

          For Everyone
          July 18, 2025

          Key points


          Seasonal influenza activity is low.

          U.S. virologic surveillance

          Clinical Laboratories


          The results of tests performed by clinical laboratories nationwide are summarized below. Data from clinical laboratories (the percentage of specimens tested that are positive for influenza) are used to monitor whether influenza activity is increasing or decreasing. Nationally, during Week 28, the percentage of respiratory specimens testing positive for influenza virus in clinical laboratories was 0.8%.
          No. of specimens tested 29,685 3,706,766
          No. of positive specimens (%) 243 (0.8%) 488,429 (13.2%)
          Positive specimens by type
          Influenza A 137 (56.4%) 434,146 (88.9%)
          Influenza B 106 (43.6%) 54,283 (11.1%)
          Public Health Laboratories


          The results of tests performed by public health laboratories nationwide are summarized below. Data from public health laboratories are used to monitor the proportion of circulating viruses that belong to each influenza virus type/subtype/lineage. Viruses known to be associated with recent live attenuated influenza vaccine (LAIV) receipt or found upon further testing to be a vaccine virus are not included as they are not circulating influenza viruses.
          No. of specimens tested 463 150,130
          No. of positive specimens 15 99,170
          Positive specimens by type/subtype
          Influenza A 15 (100%) 93,379 (94.2%)
          Subtyping Performed 10 (66.7%) 83,769 (89.7%)
          (H1N1)pdm09 10 (100%) 44,278 (52.9%)
          H3N2 0 39,412 (47.0%)
          H3N2v 0 0
          H5* 0 79 (0.1%)
          Subtyping not performed 5 (33.3%) 9,610 (10.3%)
          Influenza B 0 5,791 (5.8%)
          Lineage testing performed 0 3,230 (55.8%)
          Yamagata lineage 0 0
          Victoria lineage 0 3,230 (100%)
          Lineage not performed 0 2,561 (44.2%)
          *These data reflect specimens tested, and the number determined to be positive for influenza viruses at the public health labs (specimens tested is not the same as cases). The data do not reflect specimens tested only at CDC and could include more than one specimen tested per person. The guidance for avian influenza A(H5) virus testing recommends testing both a conjunctival and respiratory swab for people with conjunctivitis which has resulted in more specimens testing positive for avian influenza A(H5) virus than the number of human A(H5) cases. For more information on the number of people infected with avian influenza A(H5) viruses, please visit the "How CDC is monitoring influenza data among people to better understand the current avian influenza A (H5N1) situation"

          When an influenza virus that normally circulates in swine (but not people) is detected in a person, it is called a "variant" influenza virus. Most human infections with variant influenza viruses occur following exposure to swine, but human-to-human transmission can occur. It is important to note that in most cases, variant influenza viruses have not shown the ability to spread easily and sustainably from human-to-human.



          *This graph reflects the number of specimens tested and the number determined to be positive for influenza viruses at the public health lab (specimens tested is not the same as cases). It does not reflect specimens tested only at CDC and could include more than one specimen tested per person. Specimens tested as part of routine influenza surveillance as well as those tested as part of targeted testing for people exposed to avian influenza A(H5) are included.

          Additional virologic surveillance information for current and past seasons:

          Surveillance Methods | FluView Interactive: National, Regional, and State Data or Age Data

          Novel Influenza A Virus Infections


          No confirmed human infections with influenza A(H5) virus were reported to CDC this week. To date, human-to-human transmission of avian influenza A(H5) virus (H5 bird flu) has not been identified in the United States.

          The CSTE position statement, which includes updated case definitions for confirmed, probable, and suspected cases is available at http://www.cste.org/resource/resmgr/...nfluenza_A.pdf.

          An up-to-date human case summary during the current outbreak by state and exposure source is available at www.cdc.gov/bird-flu/situation-summary/index.html.

          Information about avian influenza is available at https://www.cdc.gov/flu/avianflu/index.htm.

          A(H5N1) virus interim recommendations for Prevention, Monitoring, and Public Health Investigations are available at https://www.cdc.gov/bird-flu/prevent...endations.html.

          The latest case reports on avian influenza outbreaks in wild birds, commercial poultry, backyard or hobbyist flocks, and mammals in the United States are available from the USDA at https://www.aphis.usda.gov/h5n1-hpai#detections-hpai.

          Additional information regarding human infections with novel influenza A viruses:

          Surveillance Methods | FluView Interactive


          Outpatient and Emergency Department Illness Surveillance

          Outpatient Respiratory Illness Visits


          The U.S. Outpatient Influenza-like Illness Surveillance Network (ILINet) monitors outpatient visits for respiratory illness referred to as influenza-like illness [ILI (fever plus cough or sore throat)], not laboratory-confirmed influenza, and may capture respiratory illness visits due to infection with any pathogen that can present with similar symptoms, including influenza, SARS-CoV-2, and RSV. Therefore, it is important to evaluate syndromic surveillance data, including that from ILINet, in the context of other sources of surveillance data to obtain a complete and accurate picture of influenza, SARS-CoV-2, and other respiratory virus activity.

          Nationally, during Week 28, 1.1% of patient visits reported through ILINet were due to respiratory illness that included fever plus a cough or sore throat, also referred to as ILI. Multiple respiratory viruses are co-circulating, and the relative contribution of influenza virus infection to ILI varies by location.

          Outpatient Respiratory Illness Visits by Age Group


          More than 70% of ILINet participants provide both the number of patient visits for respiratory illness and the total number of patient visits for the week broken out by age group. Data from this subset of providers are used to calculate the percentages of patient visits for respiratory illness by age group.

          During Week 28, the percentage of visits for respiratory illness reported in ILINet was 3.6% among those 0-4 years, 1.4% among those 5-24 years, 0.9% among those 25-49 years, 0.7% among those 50-64 years, and 0.5% among those 65 years and older.

          Outpatient Respiratory Illness Activity Map


          Data collected in ILINet are used to produce a measure of ILI activity* by state/jurisdiction and Core Based Statistical Areas (CBSA).
          Week 28
          (Week ending
          Jul. 12, 2025)
          Week 27
          (Week ending
          Jul. 5, 2025)
          Week 28
          (Week ending
          Jul. 12, 2025)
          Week 27
          (Week ending
          Jul. 5, 2025)
          Very High 0 0 0 0
          High 0 0 0 0
          Moderate 0 0 0 0
          Low 0 0 2 1
          Minimal 54 55 679 695
          Insufficient Data 1 0 248 233

          *Data collected in ILINet may disproportionally represent certain populations within a jurisdiction or CBSA, and therefore, may not accurately depict the full picture of influenza activity for the entire jurisdiction or CBSA. Differences in the data presented here by CDC and independently by some health departments likely represent differing levels of data completeness with data presented by the health department likely being the more complete.

          Additional information about medically attended visits for ILI for current and past seasons:

          Surveillance Methods | FluView Interactive: National, Regional, and State Data or ILI Activity Map

          National Syndromic Surveillance System (NSSP)


          The overall percentage of emergency department (ED) visits with a discharge diagnosis of influenza reported in NSSP was 0.1% during Week 28. The percentage of visits was 0.3% among those 0-4 years, 0.2% among those 5-17 years, 0.1% among those 18-64 years, and 0.1% among those 65 years and older. RegionNationalRegion 1Region 2Region 3Region 4Region 5Region 6Region 7Region 8Region 9Region 10
          Season2023-2024 & 2024-20252022-2023 Skip Over Chart Container
          2.0%4.0%6.0%8.0%10.0%12.0%14.0%16.0%Percent of Emergency Department Visits for InfluenzaWeek 43 of 2023Week 47 of 2023Week 51 of 2023Week 3 of 2024Week 7 of 2024Week 11 of 2024Week 15 of 2024Week 19 of 2024Week 23 of 2024Week 27 of 2024Week 31 of 2024Week 35 of 2024Week 39 of 2024Week 43 of 2024Week 47 of 2024Week 51 of 2024Week 3 of 2025Week 7 of 2025Week 11 of 2025Week 15 of 2025Week 19 of 2025Week 23 of 2025Week 27 of 2025 Age Group

          Skip Data Table
          Data Table Download Data (CSV) Skipped data table.

          Additional information about emergency department visits for flu for current and past seasons:‎‎‎

          Surveillance Methods | Emergency Department Visits for COVID-19, flu, and RSV


          Hospitalization Surveillance

          FluSurv-Net


          The Influenza Hospitalization Surveillance Network (FluSurv-NET) conducts population-based surveillance for laboratory-confirmed influenza-related hospitalizations in select counties in 14 states and represents approximately 9% of the U.S. population. FluSurv-NET hospitalization data are preliminary. Patients admitted for laboratory-confirmed influenza-related hospitalization after April 30, 2025, will not be included in FluSurv-NET for the 2024-2025 season. Data on patients admitted through April 30, 2025, will continue to be updated on FluView Interactive as additional information is received.

          Additional FluSurv-NET hospitalization surveillance information for current and past seasons and additional age groups:

          Surveillance Methods | FluView Interactive: Rates by Age, Sex, and Race/Ethnicity or Data on Patient Characteristics | RESP-NET Interactive

          National Healthcare Safety Network (NHSN) Hospital Respiratory Data


          Hospitals report to NHSN the weekly number of patients with laboratory-confirmed influenza who were admitted to the hospital. Nationally, during Week 28, 979 (0.3 per 100,000 population) laboratory-confirmed influenza-associated hospitalizations were reported. When examining rates by age, the highest hospital admission rate per 100,000 population was among those 65 years and older (0.9), followed by those 0-4 years (0.3), and the 50-64 years age group (0.2).

          Additional NHSN Hospital Respiratory Data information:

          Surveillance Methods | Additional Data | FluView Interactive

          Mortality Surveillance

          National Center for Health Statistics (NCHS) Mortality Surveillance


          Based on NCHS mortality surveillance data available on July 17, 2025, 0.1% of the deaths that occurred during the week ending July 12, 2025 (Week 28) were due to influenza. The data presented are preliminary and may change as more data are received and processed.

          Additional pneumonia, influenza and COVID-19 mortality surveillance information for current and past seasons:

          Surveillance Methods | FluView Interactive

          Influenza-Associated Pediatric Mortality


          One influenza-associated pediatric death that occurred during Week 27 (the week ending July 5, 2025) of the 2024-2025 season was reported to CDC during Week 28. A total of 261 influenza-associated pediatric deaths occurring during the 2024-2025 season have been reported to CDC. This is the highest number of pediatric deaths reported in any non-pandemic influenza season since the condition became reportable in 2004.

          Among children who were eligible for influenza vaccination and with known vaccine status, 90% of reported pediatric deaths this season (compared to 82% during the 2023-2024 season) have occurred in children who were not fully vaccinated against influenza.

          Additional pediatric mortality surveillance information for current and past seasons:

          Surveillance Methods | FluView Interactive
          All data in this report are preliminary and may change as more reports are received.

          A description of the CDC influenza surveillance system, including methodology and detailed descriptions of each data component, is available on the surveillance methods page.1

          Additional information on the current and previous influenza seasons for each surveillance component are available on FluView Interactive.

          Additional National and International Influenza Surveillance Information

          Additional surveillance information


          FluView Interactive: FluView includes enhanced web-based interactive applications that can provide dynamic visuals of the influenza data collected and analyzed by CDC. These FluView Interactive applications allow people to create customized, visual interpretations of influenza data, as well as make comparisons across flu seasons, regions, age groups and a variety of other demographics.

          National Institute for Occupational Safety and Health: Monthly surveillance data on the prevalence of health-related workplace absenteeism among full-time workers in the United States are available from NIOSH.

          Comment


          • #35
            Weekly US Influenza Surveillance Report: Key Updates for Week 29, ending July 19, 2025

            For Everyone
            July 25, 2025 Key points


            Seasonal influenza activity is low.
            U.S. virologic surveillance

            Clinical Laboratories


            The results of tests performed by clinical laboratories nationwide are summarized below. Data from clinical laboratories (the percentage of specimens tested that are positive for influenza) are used to monitor whether influenza activity is increasing or decreasing. Nationally, during Week 29, the percentage of respiratory specimens testing positive for influenza virus in clinical laboratories was 0.6%.
            No. of specimens tested 26,022 3,740,636
            No. of positive specimens (%) 142 (0.6%) 488,614 (13.1%)
            Positive specimens by type
            Influenza A 93 (65.5%) 434,258 (88.9%)
            Influenza B 49 (34.5%) 54,356 (11.1%)
            Public Health Laboratories


            The results of tests performed by public health laboratories nationwide are summarized below. Data from public health laboratories are used to monitor the proportion of circulating viruses that belong to each influenza virus type/subtype/lineage. Viruses known to be associated with recent live attenuated influenza vaccine (LAIV) receipt or found upon further testing to be a vaccine virus are not included as they are not circulating influenza viruses.
            No. of specimens tested 226 150,515
            No. of positive specimens 17 99,265
            Positive specimens by type/subtype
            Influenza A 12 (70.6%) 93,447 (94.1%)
            Subtyping Performed 8 (66.7%) 83,850 (89.7%)
            (H1N1)pdm09 8 (100%) 44,351 (52.9%)
            H3N2 0 39,420 (47.0%)
            H3N2v 0 0
            H5 0 79 (0.1%)
            Subtyping not performed 4 (33.3%) 9,597 (10.3%)
            Influenza B 5 (29.4%) 5,818 (5.9%)
            Lineage testing performed 3 (60.0%) 3,254 (55.9%)
            Yamagata lineage 0 0
            Victoria lineage 3 (100%) 3,254 (100%)
            Lineage not performed 2 (40.0%) 2,564 (44.1%)
            *These data reflect specimens tested, and the number determined to be positive for influenza viruses at the public health labs (specimens tested is not the same as cases). The data do not reflect specimens tested only at CDC and could include more than one specimen tested per person. The guidance for avian influenza A(H5) virus testing recommends testing both a conjunctival and respiratory swab for people with conjunctivitis which has resulted in more specimens testing positive for avian influenza A(H5) virus than the number of human A(H5) cases. For more information on the number of people infected with avian influenza A(H5) viruses, please visit the "How CDC is monitoring influenza data among people to better understand the current avian influenza A (H5N1) situation"

            When an influenza virus that normally circulates in swine (but not people) is detected in a person, it is called a "variant" influenza virus. Most human infections with variant influenza viruses occur following exposure to swine, but human-to-human transmission can occur. It is important to note that in most cases, variant influenza viruses have not shown the ability to spread easily and sustainably from human-to-human.



            *This graph reflects the number of specimens tested and the number determined to be positive for influenza viruses at the public health lab (specimens tested is not the same as cases). It does not reflect specimens tested only at CDC and could include more than one specimen tested per person. Specimens tested as part of routine influenza surveillance as well as those tested as part of targeted testing for people exposed to avian influenza A(H5) are included.

            Additional virologic surveillance information for current and past seasons:

            Surveillance Methods | FluView Interactive: National, Regional, and State Data or Age Data

            Novel Influenza A Virus Infections


            No confirmed human infections with influenza A(H5) virus were reported to CDC this week. To date, human-to-human transmission of avian influenza A(H5) virus (H5 bird flu) has not been identified in the United States.

            The CSTE position statement, which includes updated case definitions for confirmed, probable, and suspected cases is available at http://www.cste.org/resource/resmgr/...nfluenza_A.pdf.

            An up-to-date human case summary during the current outbreak by state and exposure source is available at www.cdc.gov/bird-flu/situation-summary/index.html.

            Information about avian influenza is available at https://www.cdc.gov/flu/avianflu/index.htm.

            A(H5N1) virus interim recommendations for Prevention, Monitoring, and Public Health Investigations are available at https://www.cdc.gov/bird-flu/prevent...endations.html.

            The latest case reports on avian influenza outbreaks in wild birds, commercial poultry, backyard or hobbyist flocks, and mammals in the United States are available from the USDA at https://www.aphis.usda.gov/h5n1-hpai#detections-hpai.

            Additional information regarding human infections with novel influenza A viruses:

            Surveillance Methods | FluView Interactive

            Outpatient Respiratory Illness Surveillance


            The U.S. Outpatient Influenza-like Illness Surveillance Network (ILINet) monitors outpatient visits for respiratory illness referred to as influenza-like illness [ILI (fever plus cough or sore throat)], not laboratory-confirmed influenza, and may capture respiratory illness visits due to infection with any pathogen that can present with similar symptoms, including influenza, SARS-CoV-2, and RSV. Therefore, it is important to evaluate syndromic surveillance data, including that from ILINet, in the context of other sources of surveillance data to obtain a complete and accurate picture of influenza, SARS-CoV-2, and other respiratory virus activity.

            Outpatient Respiratory Illness Visits


            Nationally, during Week 29, 1.0% of patient visits reported through ILINet were due to respiratory illness that included fever plus a cough or sore throat, also referred to as ILI. Multiple respiratory viruses are co-circulating, and the relative contribution of influenza virus infection to ILI varies by location.

            Outpatient Respiratory Illness Visits by Age Group


            More than 70% of ILINet participants provide both the number of patient visits for respiratory illness and the total number of patient visits for the week broken out by age group. Data from this subset of providers are used to calculate the percentages of patient visits for respiratory illness by age group.

            During Week 29, the percentage of visits for respiratory illness reported in ILINet was 3.2% among those 0-4 years, 1.3% among those 5-24 years, 0.9% among those 25-49 years, 0.7% among those 50-64 years, and 0.5% among those 65 years and older.

            Outpatient Respiratory Illness Activity Map


            Data collected in ILINet are used to produce a measure of ILI activity* by state/jurisdiction and Core Based Statistical Areas (CBSA).
            Week 29
            (Week ending
            Jul. 19, 2025)
            Week 28
            (Week ending
            Jul. 12, 2025)
            Week 29
            (Week ending
            Jul. 19, 2025)
            Week 28
            (Week ending
            Jul. 12, 2025)
            Very High 0 0 0 0
            High 0 0 0 0
            Moderate 0 0 0 0
            Low 0 0 0 2
            Minimal 55 54 683 680
            Insufficient Data 0 1 246 247

            *Data collected in ILINet may disproportionally represent certain populations within a jurisdiction or CBSA, and therefore, may not accurately depict the full picture of influenza activity for the entire jurisdiction or CBSA. Differences in the data presented here by CDC and independently by some health departments likely represent differing levels of data completeness with data presented by the health department likely being the more complete.

            Additional information about medically attended visits for ILI for current and past seasons:

            Surveillance Methods | FluView Interactive: National, Regional, and State Data or ILI Activity Map

            National Syndromic Surveillance System (NSSP)


            The overall percentage of emergency department (ED) visits with a discharge diagnosis of influenza reported in NSSP was 0.1% during Week 29. The percentage of visits was 0.2% among those 0-4 years, 0.1% among those 5-17 years, 0.1% among those 18-64 years, and 0.1% among those 65 years and older. RegionNationalRegion 1Region 2Region 3Region 4Region 5Region 6Region 7Region 8Region 9Region 10
            Season2023-2024 & 2024-20252022-2023 Skip Over Chart Container
            2.0%4.0%6.0%8.0%10.0%12.0%14.0%16.0%Percent of Emergency Department Visits for InfluenzaWeek 41 of 2023Week 45 of 2023Week 49 of 2023Week 1 of 2024Week 5 of 2024Week 9 of 2024Week 13 of 2024Week 17 of 2024Week 21 of 2024Week 25 of 2024Week 29 of 2024Week 33 of 2024Week 37 of 2024Week 41 of 2024Week 45 of 2024Week 49 of 2024Week 1 of 2025Week 5 of 2025Week 9 of 2025Week 13 of 2025Week 17 of 2025Week 21 of 2025Week 25 of 2025Week 29 of 2025

            Age Group

            Skip Data Table
            Data Table Download Data (CSV) Skipped data table.

            Additional information about emergency department visits for flu for current and past seasons:‎‎‎

            Surveillance Methods | Emergency Department Visits for COVID-19, flu, and RSV

            Hospitalization Surveillance

            FluSurv-Net


            The Influenza Hospitalization Surveillance Network (FluSurv-NET) conducts population-based surveillance for laboratory-confirmed influenza-related hospitalizations in select counties in 14 states and represents approximately 9% of the U.S. population. FluSurv-NET hospitalization data are preliminary. Patients admitted for laboratory-confirmed influenza-related hospitalization after April 30, 2025, will not be included in FluSurv-NET for the 2024-2025 season. Data on patients admitted through April 30, 2025, will continue to be updated on FluView Interactive as additional information is received.

            Additional FluSurv-NET hospitalization surveillance information for current and past seasons and additional age groups:

            Surveillance Methods | FluView Interactive: Rates by Age, Sex, and Race/Ethnicity or Data on Patient Characteristics | RESP-NET Interactive

            National Healthcare Safety Network (NHSN) Hospital Respiratory Data


            Hospitals report to NHSN the weekly number of patients with laboratory-confirmed influenza who were admitted to the hospital. Nationally, during Week 29, 787 (0.2 per 100,000 population) laboratory-confirmed influenza-associated hospitalizations were reported. When examining rates by age, the highest hospital admission rate per 100,000 population was among those 65 years and older (0.7), followed by those 0-4 years (0.3), and the 50-64 years age group (0.2).

            Additional NHSN Hospital Respiratory Data information:

            Surveillance Methods | Additional Data | FluView Interactive
            Mortality Surveillance

            National Center for Health Statistics (NCHS) Mortality Surveillance


            Based on NCHS mortality surveillance data available on July 24, 2025, 0.04% of the deaths that occurred during the week ending July 19, 2025 (Week 29) were due to influenza. The data presented are preliminary and may change as more data are received and processed.

            Additional pneumonia, influenza and COVID-19 mortality surveillance information for current and past seasons:

            Surveillance Methods | FluView Interactive

            Influenza-Associated Pediatric Mortality


            Five influenza-associated pediatric deaths occurring during the 2024-2025 season were reported to CDC during Week 29. The deaths occurred during weeks 8, 9, 19, 24 and 27 (the weeks ending February 22, March 1, May 10, June 14, and July 5, 2025, respectively). A total of 266 influenza-associated pediatric deaths occurring during the 2024-2025 season have been reported to CDC. This is the highest number of pediatric deaths reported in any non-pandemic influenza season since the condition became reportable in 2004. Among children who were eligible for influenza vaccination and with known vaccine status, 90% of reported pediatric deaths this season (compared to 82% during the 2023-2024 season) have occurred in children who were not fully vaccinated against influenza.

            One death occurring in the 2023-2024 season during Week 2 (the week ending January 13, 2024) was also reported. This brings the total number of pediatric deaths for last season to 208.

            Additional pediatric mortality surveillance information for current and past seasons:

            Surveillance Methods | FluView Interactive
            All data in this report are preliminary and may change as more reports are received.

            A description of the CDC influenza surveillance system, including methodology and detailed descriptions of each data component, is available on the surveillance methods page.1

            Additional information on the current and previous influenza seasons for each surveillance component are available on FluView Interactive.

            Additional National and International Influenza Surveillance Information

            Additional surveillance information


            FluView Interactive: FluView includes enhanced web-based interactive applications that can provide dynamic visuals of the influenza data collected and analyzed by CDC. These FluView Interactive applications allow people to create customized, visual interpretations of influenza data, as well as make comparisons across flu seasons, regions, age groups and a variety of other demographics.

            National Institute for Occupational Safety and Health: Monthly surveillance data on the prevalence of health-related workplace absenteeism among full-time workers in the United States are available from NIOSH.

            Comment


            • #36
              Weekly US Influenza Surveillance Report: Key Updates for Week 30, ending July 26, 2025

              For Everyone
              Aug. 1, 2025

              Key points


              Seasonal influenza activity is low.
              U.S. virologic surveillance

              Clinical Laboratories


              The results of tests performed by clinical laboratories nationwide are summarized below. Data from clinical laboratories (the percentage of specimens tested that are positive for influenza) are used to monitor whether influenza activity is increasing or decreasing. Nationally, during Week 30, the percentage of respiratory specimens testing positive for influenza virus in clinical laboratories was 0.4%.
              No. of specimens tested 25,876 3,771,794
              No. of positive specimens (%) 100 (0.4%) 488,745 (13.0%)
              Positive specimens by type
              Influenza A 78 (78.0%) 434,356 (88.9%)
              Influenza B 22 (22.0%) 54,389 (11.1%)
              Public Health Laboratories


              The results of tests performed by public health laboratories nationwide are summarized below. Data from public health laboratories are used to monitor the proportion of circulating viruses that belong to each influenza virus type/subtype/lineage. Viruses known to be associated with recent live attenuated influenza vaccine (LAIV) receipt or found upon further testing to be a vaccine virus are not included as they are not circulating influenza viruses.
              No. of specimens tested 247 151,254
              No. of positive specimens 31 99,414
              Positive specimens by type/subtype
              Influenza A 26 (83.9%) 93,553 (94.1%)
              Subtyping Performed 23 (88.5%) 83,978 (89.8%)
              (H1N1)pdm09 17 (73.9%) 44,447 (52.9%)
              H3N2 6 (26.1%) 39,452 (47.0%)
              H3N2v 0 0
              H5* 0 79 (0.1%)
              Subtyping not performed 3 (11.5%) 9,575 (10.2%)
              Influenza B 5 (16.1%) 5,861 (5.9%)
              Lineage testing performed 1 (20.0%) 3,290 (56.1%)
              Yamagata lineage 0 0
              Victoria lineage 1 (100%) 3,290 (100%)
              Lineage not performed 4 (80.0%) 2,571 (43.9%)
              *These data reflect specimens tested, and the number determined to be positive for influenza viruses at the public health labs (specimens tested is not the same as cases). The data do not reflect specimens tested only at CDC and could include more than one specimen tested per person. The guidance for avian influenza A(H5) virus testing recommends testing both a conjunctival and respiratory swab for people with conjunctivitis which has resulted in more specimens testing positive for avian influenza A(H5) virus than the number of human A(H5) cases. For more information on the number of people infected with avian influenza A(H5) viruses, please visit the "How CDC is monitoring influenza data among people to better understand the current avian influenza A (H5N1) situation"

              When an influenza virus that normally circulates in swine (but not people) is detected in a person, it is called a "variant" influenza virus. Most human infections with variant influenza viruses occur following exposure to swine, but human-to-human transmission can occur. It is important to note that in most cases, variant influenza viruses have not shown the ability to spread easily and sustainably from human-to-human.



              *This graph reflects the number of specimens tested and the number determined to be positive for influenza viruses at the public health lab (specimens tested is not the same as cases). It does not reflect specimens tested only at CDC and could include more than one specimen tested per person. Specimens tested as part of routine influenza surveillance as well as those tested as part of targeted testing for people exposed to avian influenza A(H5) are included. Additional virologic surveillance information for current and past seasons:

              Surveillance Methods | FluView Interactive: National, Regional, and State Data or Age Data

              Novel Influenza A Virus Infections


              No confirmed human infections with influenza A(H5) virus were reported to CDC this week. To date, human-to-human transmission of avian influenza A(H5) virus (H5 bird flu) has not been identified in the United States.

              The CSTE position statement, which includes updated case definitions for confirmed, probable, and suspected cases is available at http://www.cste.org/resource/resmgr/...nfluenza_A.pdf.

              An up-to-date human case summary during the current outbreak by state and exposure source is available at www.cdc.gov/bird-flu/situation-summary/index.html.

              Information about avian influenza is available at https://www.cdc.gov/flu/avianflu/index.htm.

              A(H5N1) virus interim recommendations for Prevention, Monitoring, and Public Health Investigations are available at https://www.cdc.gov/bird-flu/prevent...endations.html.

              The latest case reports on avian influenza outbreaks in wild birds, commercial poultry, backyard or hobbyist flocks, and mammals in the United States are available from the USDA at https://www.aphis.usda.gov/h5n1-hpai#detections-hpai.

              Additional information regarding human infections with novel influenza A viruses:

              Surveillance Methods | FluView Interactive
              Outpatient and Emergency Department Illness Surveillance

              Outpatient Respiratory Illness Visits


              The U.S. Outpatient Influenza-like Illness Surveillance Network (ILINet) monitors outpatient visits for respiratory illness referred to as influenza-like illness [ILI (fever plus cough or sore throat)], not laboratory-confirmed influenza, and may capture respiratory illness visits due to infection with any pathogen that can present with similar symptoms, including influenza, SARS-CoV-2, and RSV. Therefore, it is important to evaluate syndromic surveillance data, including that from ILINet, in the context of other sources of surveillance data to obtain a complete and accurate picture of influenza, SARS-CoV-2, and other respiratory virus activity.

              Nationally, during Week 30, 1.0% of patient visits reported through ILINet were due to respiratory illness that included fever plus a cough or sore throat, also referred to as ILI. Multiple respiratory viruses are co-circulating, and the relative contribution of influenza virus infection to ILI varies by location.

              Outpatient Respiratory Illness Visits by Age Group


              More than 70% of ILINet participants provide both the number of patient visits for respiratory illness and the total number of patient visits for the week broken out by age group. Data from this subset of providers are used to calculate the percentages of patient visits for respiratory illness by age group.

              During Week 30, the percentage of visits for respiratory illness reported in ILINet was 3.4% among those 0-4 years, 1.4% among those 5-24 years, 0.9% among those 25-49 years, 0.6% among those 50-64 years, and 0.5% among those 65 years and older.

              Outpatient Respiratory Illness Activity Map


              Data collected in ILINet are used to produce a measure of ILI activity* by state/jurisdiction and Core Based Statistical Areas (CBSA).
              Week 30
              (Week ending
              Jul. 26, 2025)
              Week 29
              (Week ending
              Jul. 19, 2025)
              Week 30
              (Week ending
              Jul. 26, 2025)
              Week 29
              (Week ending
              Jul. 19, 2025)
              Very High 0 0 0 0
              High 0 0 0 0
              Moderate 0 0 0 0
              Low 0 0 0 0
              Minimal 55 55 692 688
              Insufficient Data 0 0 237 241

              *Data collected in ILINet may disproportionally represent certain populations within a jurisdiction or CBSA, and therefore, may not accurately depict the full picture of influenza activity for the entire jurisdiction or CBSA. Differences in the data presented here by CDC and independently by some health departments likely represent differing levels of data completeness with data presented by the health department likely being the more complete. Additional information about medically attended visits for ILI for current and past seasons:

              Surveillance Methods | FluView Interactive: National, Regional, and State Data or ILI Activity Map

              National Syndromic Surveillance System (NSSP)


              The overall percentage of emergency department (ED) visits with a discharge diagnosis of influenza reported in NSSP was 0.1% during Week 30. The percentage of visits was 0.2% among those 0-4 years and 0.1% among those 5-17 years, 18-64 years, and 65 years and older. RegionNationalRegion 1Region 2Region 3Region 4Region 5Region 6Region 7Region 8Region 9Region 10
              Season2023-2024 & 2024-20252022-2023 Skip Over Chart Container
              2.0%4.0%6.0%8.0%10.0%12.0%14.0%16.0%Percent of Emergency Department Visits for InfluenzaWeek 41 of 2023Week 45 of 2023Week 49 of 2023Week 1 of 2024Week 5 of 2024Week 9 of 2024Week 13 of 2024Week 17 of 2024Week 21 of 2024Week 25 of 2024Week 29 of 2024Week 33 of 2024Week 37 of 2024Week 41 of 2024Week 45 of 2024Week 49 of 2024Week 1 of 2025Week 5 of 2025Week 9 of 2025Week 13 of 2025Week 17 of 2025Week 21 of 2025Week 25 of 2025Week 29 of 2025

              Age Group

              Skip Data Table
              Data Table Download Data (CSV) Skipped data table.

              Additional information about emergency department visits for flu for current and past seasons:‎‎‎

              Surveillance Methods | Emergency Department Visits for COVID-19, flu, and RSV
              Hospitalization Surveillance

              FluSurv-Net


              The Influenza Hospitalization Surveillance Network (FluSurv-NET) conducts population-based surveillance for laboratory-confirmed influenza-related hospitalizations in select counties in 14 states and represents approximately 9% of the U.S. population. FluSurv-NET hospitalization data are preliminary. Patients admitted for laboratory-confirmed influenza-related hospitalization after April 30, 2025, will not be included in FluSurv-NET for the 2024-2025 season. Data on patients admitted through April 30, 2025, will continue to be updated on FluView Interactive as additional information is received.

              Additional FluSurv-NET hospitalization surveillance information for current and past seasons and additional age groups:

              Surveillance Methods | FluView Interactive: Rates by Age, Sex, and Race/Ethnicity or Data on Patient Characteristics | RESP-NET Interactive

              National Healthcare Safety Network (NHSN) Hospital Respiratory Data


              Hospitals report to NHSN the weekly number of patients with laboratory-confirmed influenza who were admitted to the hospital. Nationally, during Week 30, 825 (0.2 per 100,000 population) laboratory-confirmed influenza-associated hospitalizations were reported. When examining rates by age, the highest hospital admission rate per 100,000 population was among those 65 years and older (0.8), followed by those 0-4 years (0.3), and the 50-64 years age group (0.2).

              Additional NHSN Hospital Respiratory Data information:

              Surveillance Methods | Additional Data | FluView Interactive
              Mortality Surveillance

              National Center for Health Statistics (NCHS) Mortality Surveillance


              Based on NCHS mortality surveillance data available on July 31, 2025, 0.04% of the deaths that occurred during the week ending July 26, 2025 (Week 30) were due to influenza. The data presented are preliminary and may change as more data are received and processed.

              Additional pneumonia, influenza and COVID-19 mortality surveillance information for current and past seasons:

              Surveillance Methods | FluView Interactive

              Influenza-Associated Pediatric Mortality


              No influenza-associated pediatric deaths occurring during the 2024-2025 season were reported to CDC during Week 30. A total of 266 influenza-associated pediatric deaths occurring during the 2024-2025 season have been reported to CDC. This is the highest number of pediatric deaths reported in any non-pandemic influenza season since the condition became reportable in 2004. Among children who were eligible for influenza vaccination and with known vaccine status, 90% of reported pediatric deaths this season (compared to 82% during the 2023-2024 season) have occurred in children who were not fully vaccinated against influenza.

              One death occurring in the 2023-2024 season during Week 1 (the week ending January 6, 2024) was reported to CDC during week 30. This brings the total number of pediatric deaths for last season to 209.

              Additional pediatric mortality surveillance information for current and past seasons:

              Surveillance Methods | FluView Interactive
              All data in this report are preliminary and may change as more reports are received.

              A description of the CDC influenza surveillance system, including methodology and detailed descriptions of each data component, is available on the surveillance methods page.1

              Additional information on the current and previous influenza seasons for each surveillance component are available on FluView Interactive.

              Additional National and International Influenza Surveillance Information

              Additional surveillance information


              FluView Interactive: FluView includes enhanced web-based interactive applications that can provide dynamic visuals of the influenza data collected and analyzed by CDC. These FluView Interactive applications allow people to create customized, visual interpretations of influenza data, as well as make comparisons across flu seasons, regions, age groups and a variety of other demographics.

              National Institute for Occupational Safety and Health: Monthly surveillance data on the prevalence of health-related workplace absenteeism among full-time workers in the United States are available from NIOSH.

              Comment


              • #37
                Weekly US Influenza Surveillance Report: Key Updates for Week 31, ending August 2, 2025

                For Everyone
                Aug. 8, 2025 Key points


                Seasonal influenza activity is low.
                U.S. virologic surveillance

                Clinical Laboratories


                The results of tests performed by clinical laboratories nationwide are summarized below. Data from clinical laboratories (the percentage of specimens tested that are positive for influenza) are used to monitor whether influenza activity is increasing or decreasing. Nationally, during Week 31, the percentage of respiratory specimens testing positive for influenza virus in clinical laboratories was 0.4%.
                No. of specimens tested 24,335 3,802,325
                No. of positive specimens (%) 94 (0.4%) 488,889 (12.9%)
                Positive specimens by type
                Influenza A 70 (74.5%) 434,454 (88.9%)
                Influenza B 24 (25.5%) 54,435 (11.1%)
                Public Health Laboratories


                The results of tests performed by public health laboratories nationwide are summarized below. Data from public health laboratories are used to monitor the proportion of circulating viruses that belong to each influenza virus type/subtype/lineage. Viruses known to be associated with recent live attenuated influenza vaccine (LAIV) receipt or found upon further testing to be a vaccine virus are not included as they are not circulating influenza viruses.
                No. of specimens tested 294 152,238
                No. of positive specimens 35 99,557
                Positive specimens by type/subtype
                Influenza A 34 (97.1%) 93,674 (94.1%)
                Subtyping Performed 26 (76.5%) 84,080 (89.8%)
                (H1N1)pdm09 24 (92.3%) 44,511 (52.9%)
                H3N2 2 (7.7%) 39,490 (47.0%)
                H3N2v 0 0
                H5 0 79 (0.1%)
                Subtyping not performed 8 (23.5%) 9,594 (10.2%)
                Influenza B 1 (2.9%) 5,883 (5.9%)
                Lineage testing performed 0 3,308 (56.2%)
                Yamagata lineage 0 0
                Victoria lineage 0 3,308 (100%)
                Lineage not performed 1 (100%) 2,575 (43.8%)

                *This graph reflects the number of specimens tested and the number determined to be positive for influenza viruses at the public health lab (specimens tested is not the same as cases). It does not reflect specimens tested only at CDC and could include more than one specimen tested per person. Specimens tested as part of routine influenza surveillance as well as those tested as part of targeted testing for people exposed to avian influenza A(H5) are included.

                Additional virologic surveillance information for current and past seasons:

                Surveillance Methods | FluView Interactive: National, Regional, and State Data or Age Data

                Novel Influenza A Virus Infections


                No confirmed human infections with influenza A(H5) virus were reported to CDC this week. To date, human-to-human transmission of avian influenza A(H5) virus (H5 bird flu) has not been identified in the United States.

                The CSTE position statement, which includes updated case definitions for confirmed, probable, and suspected cases is available at http://www.cste.org/resource/resmgr/...nfluenza_A.pdf.

                An up-to-date human case summary during the current outbreak by state and exposure source is available at www.cdc.gov/bird-flu/situation-summary/index.html.

                Information about avian influenza is available at https://www.cdc.gov/flu/avianflu/index.htm.

                A(H5N1) virus interim recommendations for Prevention, Monitoring, and Public Health Investigations are available at https://www.cdc.gov/bird-flu/prevent...endations.html.

                The latest case reports on avian influenza outbreaks in wild birds, commercial poultry, backyard or hobbyist flocks, and mammals in the United States are available from the USDA at https://www.aphis.usda.gov/h5n1-hpai#detections-hpai.

                Additional information regarding human infections with novel influenza A viruses:

                Surveillance Methods | FluView Interactive
                Outpatient Respiratory Illness Surveillance


                The U.S. Outpatient Influenza-like Illness Surveillance Network (ILINet) monitors outpatient visits for respiratory illness referred to as influenza-like illness [ILI (fever plus cough or sore throat)], not laboratory-confirmed influenza, and may capture respiratory illness visits due to infection with any pathogen that can present with similar symptoms, including influenza, SARS-CoV-2, and RSV. Therefore, it is important to evaluate syndromic surveillance data, including that from ILINet, in the context of other sources of surveillance data to obtain a complete and accurate picture of influenza, SARS-CoV-2, and other respiratory virus activity.

                Outpatient Respiratory Illness Visits


                Nationally, during Week 31, 1.0% of patient visits reported through ILINet were due to respiratory illness that included fever plus a cough or sore throat, also referred to as ILI. Multiple respiratory viruses are co-circulating, and the relative contribution of influenza virus infection to ILI varies by location.

                Outpatient Respiratory Illness Visits by Age Group


                More than 70% of ILINet participants provide both the number of patient visits for respiratory illness and the total number of patient visits for the week broken out by age group. Data from this subset of providers are used to calculate the percentages of patient visits for respiratory illness by age group.

                During Week 31, the percentage of visits for respiratory illness reported in ILINet was 3.4% among those 0-4 years, 1.4% among those 5-24 years, 0.9% among those 25-49 years, 0.6% among those 50-64 years, and 0.5% among those 65 years and older.

                Outpatient Respiratory Illness Activity Map


                Data collected in ILINet are used to produce a measure of ILI activity* by state/jurisdiction and Core Based Statistical Areas (CBSA).
                Week 31
                (Week ending
                Aug. 2, 2025)
                Week 30
                (Week ending
                Jul. 26, 2025)
                Week 31
                (Week ending
                Aug. 2, 2025)
                Week 30
                (Week ending
                Jul. 26, 2025)
                Very High 0 0 0 0
                High 0 0 0 0
                Moderate 0 0 0 0
                Low 0 0 0 2
                Minimal 55 55 682 694
                Insufficient Data 0 0 247 235

                *Data collected in ILINet may disproportionally represent certain populations within a jurisdiction or CBSA, and therefore, may not accurately depict the full picture of influenza activity for the entire jurisdiction or CBSA. Differences in the data presented here by CDC and independently by some health departments likely represent differing levels of data completeness with data presented by the health department likely being the more complete.

                Additional information about medically attended visits for ILI for current and past seasons:

                Surveillance Methods | FluView Interactive: National, Regional, and State Data or ILI Activity Map

                National Syndromic Surveillance System (NSSP)


                The overall percentage of emergency department (ED) visits with a discharge diagnosis of influenza reported in NSSP was 0.1% during Week 31. The percentage of visits was 0.2% among those 0-4 years, and 0.1% among those 5-17 years, 18-64 years, and 65 years and older. RegionNationalRegion 1Region 2Region 3Region 4Region 5Region 6Region 7Region 8Region 9Region 10
                Season2023-2024 & 2024-20252022-2023 Skip Over Chart Container
                2.0%4.0%6.0%8.0%10.0%12.0%14.0%16.0%Percent of Emergency Department Visits for InfluenzaWeek 43 of 2023Week 47 of 2023Week 51 of 2023Week 3 of 2024Week 7 of 2024Week 11 of 2024Week 15 of 2024Week 19 of 2024Week 23 of 2024Week 27 of 2024Week 31 of 2024Week 35 of 2024Week 39 of 2024Week 43 of 2024Week 47 of 2024Week 51 of 2024Week 3 of 2025Week 7 of 2025Week 11 of 2025Week 15 of 2025Week 19 of 2025Week 23 of 2025Week 27 of 2025Week 31 of 2025

                Age Group

                Skip Data Table
                Data Table Download Data (CSV) Skipped data table.

                Additional information about emergency department visits for flu for current and past seasons:‎‎‎

                Surveillance Methods | Emergency Department Visits for COVID-19, flu, and RSV
                Hospitalization Surveillance

                FluSurv-Net


                The Influenza Hospitalization Surveillance Network (FluSurv-NET) conducts population-based surveillance for laboratory-confirmed influenza-related hospitalizations in select counties in 14 states and represents approximately 9% of the U.S. population. FluSurv-NET hospitalization data are preliminary. Patients admitted for laboratory-confirmed influenza-related hospitalization after April 30, 2025, will not be included in FluSurv-NET for the 2024-2025 season. Data on patients admitted through April 30, 2025, will continue to be updated on FluView Interactive as additional information is received.

                Additional FluSurv-NET hospitalization surveillance information for current and past seasons and additional age groups:

                Surveillance Methods | FluView Interactive: Rates by Age, Sex, and Race/Ethnicity or Data on Patient Characteristics | RESP-NET Interactive

                National Healthcare Safety Network (NHSN) Hospital Respiratory Data


                Hospitals report to NHSN the weekly number of patients with laboratory-confirmed influenza who were admitted to the hospital. Nationally, during Week 31, 733 (0.2 per 100,000 population) laboratory-confirmed influenza-associated hospitalizations were reported. When examining rates by age, the highest hospital admission rate per 100,000 population was among those 65 years and older (0.7), followed by those 0-4 years (0.2) and 50-64 years (0.2).

                Additional NHSN Hospital Respiratory Data information:

                Surveillance Methods | Additional Data | FluView Interactive

                Mortality Surveillance

                National Center for Health Statistics (NCHS) Mortality Surveillance


                Based on NCHS mortality surveillance data available on August 7, 2025, 0.03% of the deaths that occurred during the week ending August 2, 2025 (Week 31) were due to influenza. The data presented are preliminary and may change as more data are received and processed.

                Additional pneumonia, influenza and COVID-19 mortality surveillance information for current and past seasons:

                Surveillance Methods | FluView Interactive

                Influenza-Associated Pediatric Mortality


                One influenza-associated pediatric death that occurred during Week 16 (the week ending April 19, 2025) of the 2024-2025 season was reported to CDC during Week 31. A total of 267 influenza-associated pediatric deaths occurring during the 2024-2025 season have been reported to CDC. This is the highest number of pediatric deaths reported in any non-pandemic influenza season since the condition became reportable in 2004.

                Among children who were eligible for influenza vaccination and with known vaccine status, 90% of reported pediatric deaths this season (compared to 82% during the 2023-2024 season) have occurred in children who were not fully vaccinated against influenza.

                Additional pediatric mortality surveillance information for current and past seasons:

                Surveillance Methods | FluView Interactive
                All data in this report are preliminary and may change as more reports are received.

                A description of the CDC influenza surveillance system, including methodology and detailed descriptions of each data component, is available on the surveillance methods page.1

                Additional information on the current and previous influenza seasons for each surveillance component are available on FluView Interactive.

                Additional National and International Influenza Surveillance Information

                Additional surveillance information


                FluView Interactive: FluView includes enhanced web-based interactive applications that can provide dynamic visuals of the influenza data collected and analyzed by CDC. These FluView Interactive applications allow people to create customized, visual interpretations of influenza data, as well as make comparisons across flu seasons, regions, age groups and a variety of other demographics.

                National Institute for Occupational Safety and Health: Monthly surveillance data on the prevalence of health-related workplace absenteeism among full-time workers in the United States are available from NIOSH.

                Comment


                • #38
                  Weekly US Influenza Surveillance Report: Key Updates for Week 32, ending August 9, 2025

                  For Everyone
                  Aug. 15, 2025

                  Key points


                  Seasonal influenza activity is low.
                  U.S. virologic surveillance

                  Clinical Laboratories


                  The results of tests performed by clinical laboratories nationwide are summarized below. Data from clinical laboratories (the percentage of specimens tested that are positive for influenza) are used to monitor whether influenza activity is increasing or decreasing. Nationally, during Week 32, the percentage of respiratory specimens testing positive for influenza virus in clinical laboratories was 0.4%.
                  No. of specimens tested 28,009 3,845,643
                  No. of positive specimens (%) 116 (0.4%) 489,052 (12.7%)
                  Positive specimens by type
                  Influenza A 88 (75.9%) 434,575 (88.9%)
                  Influenza B 28 (24.1%) 54,477 (11.1%)
                  Public Health Laboratories


                  The results of tests performed by public health laboratories nationwide are summarized below. Data from public health laboratories are used to monitor the proportion of circulating viruses that belong to each influenza virus type/subtype/lineage. Viruses known to be associated with recent live attenuated influenza vaccine (LAIV) receipt or found upon further testing to be a vaccine virus are not included as they are not circulating influenza viruses.
                  No. of specimens tested 310 153,366
                  No. of positive specimens 19 99,818
                  Positive specimens by type/subtype
                  Influenza A 17 (89.5%) 93,918 (94.1%)
                  Subtyping Performed 13 (76.5%) 84,330 (89.8%)
                  (H1N1)pdm09 9 (69.2%) 44,672 (53.0%)
                  H3N2 4 (30.8%) 39,579 (46.9%)
                  H3N2v 0 0
                  H5 0 79 (0.1%)
                  Subtyping not performed 4 (23.5%) 9,588 (10.2%)
                  Influenza B 2 (10.5%) 5,900 (5.9%)
                  Lineage testing performed 1 (50.0%) 3,322 (56.3%)
                  Yamagata lineage 0 0
                  Victoria lineage 1 (100%) 3,322 (100%)
                  Lineage not performed 1 (50.0%) 2,578 (43.7%)
                  *These data reflect specimens tested, and the number determined to be positive for influenza viruses at the public health labs (specimens tested is not the same as cases). The data do not reflect specimens tested only at CDC and could include more than one specimen tested per person. The guidance for avian influenza A(H5) virus testing recommends testing both a conjunctival and respiratory swab for people with conjunctivitis which has resulted in more specimens testing positive for avian influenza A(H5) virus than the number of human A(H5) cases. For more information on the number of people infected with avian influenza A(H5) viruses, please visit the "How CDC is monitoring influenza data among people to better understand the current avian influenza A (H5N1) situation"

                  When an influenza virus that normally circulates in swine (but not people) is detected in a person, it is called a "variant" influenza virus. Most human infections with variant influenza viruses occur following exposure to swine, but human-to-human transmission can occur. It is important to note that in most cases, variant influenza viruses have not shown the ability to spread easily and sustainably from human-to-human.



                  *This graph reflects the number of specimens tested and the number determined to be positive for influenza viruses at the public health lab (specimens tested is not the same as cases). It does not reflect specimens tested only at CDC and could include more than one specimen tested per person. Specimens tested as part of routine influenza surveillance as well as those tested as part of targeted testing for people exposed to avian influenza A(H5) are included.

                  Additional virologic surveillance information for current and past seasons:

                  Surveillance Methods | FluView Interactive: National, Regional, and State Data or Age Data

                  Novel Influenza A Virus Infections


                  No confirmed human infections with influenza A(H5) virus were reported to CDC this week. To date, human-to-human transmission of avian influenza A(H5) virus (H5 bird flu) has not been identified in the United States.

                  The CSTE position statement, which includes updated case definitions for confirmed, probable, and suspected cases is available at http://www.cste.org/resource/resmgr/...nfluenza_A.pdf.

                  An up-to-date human case summary during the current outbreak by state and exposure source is available at www.cdc.gov/bird-flu/situation-summary/index.html.

                  Information about avian influenza is available at https://www.cdc.gov/flu/avianflu/index.htm.

                  A(H5N1) virus interim recommendations for Prevention, Monitoring, and Public Health Investigations are available at https://www.cdc.gov/bird-flu/prevent...endations.html.

                  The latest case reports on avian influenza outbreaks in wild birds, commercial poultry, backyard or hobbyist flocks, and mammals in the United States are available from the USDA at https://www.aphis.usda.gov/h5n1-hpai#detections-hpai.

                  Additional information regarding human infections with novel influenza A viruses:

                  Surveillance Methods | FluView Interactive
                  Outpatient and Emergency Department Illness Surveillance

                  Outpatient Respiratory Illness Visits


                  The U.S. Outpatient Influenza-like Illness Surveillance Network (ILINet) monitors outpatient visits for respiratory illness referred to as influenza-like illness [ILI (fever plus cough or sore throat)], not laboratory-confirmed influenza, and may capture respiratory illness visits due to infection with any pathogen that can present with similar symptoms, including influenza, SARS-CoV-2, and RSV. Therefore, it is important to evaluate syndromic surveillance data, including that from ILINet, in the context of other sources of surveillance data to obtain a complete and accurate picture of influenza, SARS-CoV-2, and other respiratory virus activity.

                  Nationally, during Week 32, 1.1% of patient visits reported through ILINet were due to respiratory illness that included fever plus a cough or sore throat, also referred to as ILI. Multiple respiratory viruses are co-circulating, and the relative contribution of influenza virus infection to ILI varies by location.

                  Outpatient Respiratory Illness Visits by Age Group


                  More than 70% of ILINet participants provide both the number of patient visits for respiratory illness and the total number of patient visits for the week broken out by age group. Data from this subset of providers are used to calculate the percentages of patient visits for respiratory illness by age group.

                  During Week 32, the percentage of visits for respiratory illness reported in ILINet was 3.5% among those 0-4 years, 1.5% among those 5-24 years, 1.0% among those 25-49 years, 0.7% among those 50-64 years, and 0.5% among those 65 years and older.

                  Outpatient Respiratory Illness Activity Map


                  Data collected in ILINet are used to produce a measure of ILI activity* by state/jurisdiction and Core Based Statistical Areas (CBSA).
                  Week 32
                  (Week ending
                  Aug. 9, 2025)
                  Week 31
                  (Week ending
                  Aug. 2, 2025)
                  Week 32
                  (Week ending
                  Aug. 9, 2025)
                  Week 31
                  (Week ending
                  Aug. 2, 2025)
                  Very High 0 0 0 0
                  High 0 0 0 0
                  Moderate 0 0 0 0
                  Low 0 0 2 0
                  Minimal 54 55 691 684
                  Insufficient Data 1 0 236 245

                  *Data collected in ILINet may disproportionally represent certain populations within a jurisdiction or CBSA, and therefore, may not accurately depict the full picture of influenza activity for the entire jurisdiction or CBSA. Differences in the data presented here by CDC and independently by some health departments likely represent differing levels of data completeness with data presented by the health department likely being the more complete.

                  Additional information about medically attended visits for ILI for current and past seasons:

                  Surveillance Methods | FluView Interactive: National, Regional, and State Data or ILI Activity Map

                  National Syndromic Surveillance System (NSSP)


                  The overall percentage of emergency department (ED) visits with a discharge diagnosis of influenza reported in NSSP was 0.1% during Week 32. The percentage of visits was 0.2% among those 0-4 years, and 0.1% among those 5-17 years, 18-64 years, and 65 years and older. RegionNationalRegion 1Region 2Region 3Region 4Region 5Region 6Region 7Region 8Region 9Region 10
                  Season2023-2024 & 2024-20252022-2023 Skip Over Chart Container
                  2.0%4.0%6.0%8.0%10.0%12.0%14.0%16.0%Percent of Emergency Department Visits for InfluenzaWeek 41 of 2023Week 45 of 2023Week 49 of 2023Week 1 of 2024Week 5 of 2024Week 9 of 2024Week 13 of 2024Week 17 of 2024Week 21 of 2024Week 25 of 2024Week 29 of 2024Week 33 of 2024Week 37 of 2024Week 41 of 2024Week 45 of 2024Week 49 of 2024Week 1 of 2025Week 5 of 2025Week 9 of 2025Week 13 of 2025Week 17 of 2025Week 21 of 2025Week 25 of 2025Week 29 of 2025 Age Group

                  Skip Data Table
                  Data Table Download Data (CSV) Skipped data table.

                  Additional information about emergency department visits for flu for current and past seasons:‎‎‎

                  Surveillance Methods | Emergency Department Visits for COVID-19, flu, and RSV
                  Hospitalization surveillance

                  FluSurv-Net


                  The Influenza Hospitalization Surveillance Network (FluSurv-NET) conducts population-based surveillance for laboratory-confirmed influenza-related hospitalizations in select counties in 14 states and represents approximately 9% of the U.S. population. FluSurv-NET hospitalization data are preliminary. Patients admitted for laboratory-confirmed influenza-related hospitalization after April 30, 2025, will not be included in FluSurv-NET for the 2024-2025 season. Data on patients admitted through April 30, 2025, will continue to be updated on FluView Interactive as additional information is received.

                  Additional FluSurv-NET hospitalization surveillance information for current and past seasons and additional age groups:

                  Surveillance Methods | FluView Interactive: Rates by Age, Sex, and Race/Ethnicity or Data on Patient Characteristics | RESP-NET Interactive

                  National Healthcare Safety Network (NHSN) Hospital Respiratory Data


                  Hospitals report to NHSN the weekly number of patients with laboratory-confirmed influenza who were admitted to the hospital. Nationally, during Week 32, 705 (0.2 per 100,000 population) laboratory-confirmed influenza-associated hospitalizations were reported. When examining rates by age, the highest hospital admission rate per 100,000 population was among those 65 years and older (0.7), followed by those 50-64 years (0.2) and 0-4 years (0.1).

                  Additional NHSN Hospital Respiratory Data information:

                  Surveillance Methods | Additional Data | FluView Interactive
                  Mortality surveillance

                  National Center for Health Statistics (NCHS) Mortality Surveillance


                  Based on NCHS mortality surveillance data available on August 14, 2025, 0.02% of the deaths that occurred during the week ending August 9, 2025 (Week 32) were due to influenza. The data presented are preliminary and may change as more data are received and processed.

                  Additional pneumonia, influenza and COVID-19 mortality surveillance information for current and past seasons:

                  Surveillance Methods | FluView Interactive

                  Influenza-Associated Pediatric Mortality


                  Three influenza-associated pediatric deaths occurring during the 2024-2025 season were reported to CDC during Week 32. The deaths occurred during week 48 of 2024 (the week ending November 30, 2024) and week 9 of 2025 (the week ending March 1, 2025). A total of 270 influenza-associated pediatric deaths occurring during the 2024-2025 season have been reported to CDC. This is the highest number of pediatric deaths reported in any non-pandemic influenza season since the condition became reportable in 2004.

                  Among children who were eligible for influenza vaccination and with known vaccine status, 90% of reported pediatric deaths this season (compared to 82% during the 2023-2024 season) have occurred in children who were not fully vaccinated against influenza.

                  Additional pediatric mortality surveillance information for current and past seasons:

                  Surveillance Methods | FluView Interactive
                  All data in this report are preliminary and may change as more reports are received.

                  A description of the CDC influenza surveillance system, including methodology and detailed descriptions of each data component, is available on the surveillance methods page.1

                  Additional information on the current and previous influenza seasons for each surveillance component are available on FluView Interactive.

                  Additional National and International Influenza Surveillance Information

                  Additional surveillance information


                  FluView Interactive: FluView includes enhanced web-based interactive applications that can provide dynamic visuals of the influenza data collected and analyzed by CDC. These FluView Interactive applications allow people to create customized, visual interpretations of influenza data, as well as make comparisons across flu seasons, regions, age groups and a variety of other demographics.

                  National Institute for Occupational Safety and Health: Monthly surveillance data on the prevalence of health-related workplace absenteeism among full-time workers in the United States are available from NIOSH.

                  Comment


                  • #39
                    Weekly US Influenza Surveillance Report: Key Updates for Week 33, ending August 16, 2025

                    For Everyone
                    Aug. 22, 2025

                    Key points


                    Seasonal influenza activity is low.

                    U.S. virologic surveillance

                    Clinical Laboratories


                    The results of tests performed by clinical laboratories nationwide are summarized below. Data from clinical laboratories (the percentage of specimens tested that are positive for influenza) are used to monitor whether influenza activity is increasing or decreasing. Nationally, during Week 33, the percentage of respiratory specimens testing positive for influenza virus in clinical laboratories was 0.3%.
                    No. of specimens tested 31,830 3,887,178
                    No. of positive specimens (%) 100 (0.3%) 489,182 (12.6%)
                    Positive specimens by type
                    Influenza A 81 (81.0%) 434,683 (88.9%)
                    Influenza B 19 (19.0%) 54,499 (11.1%)
                    Public Health Laboratories


                    The results of tests performed by public health laboratories nationwide are summarized below. Data from public health laboratories are used to monitor the proportion of circulating viruses that belong to each influenza virus type/subtype/lineage. Viruses known to be associated with recent live attenuated influenza vaccine (LAIV) receipt or found upon further testing to be a vaccine virus are not included as they are not circulating influenza viruses.
                    No. of specimens tested 338 153,988
                    No. of positive specimens 15 99,853
                    Positive specimens by type/subtype
                    Influenza A 13 (86.7%) 93,946 (94.1%)
                    Subtyping Performed 11 (84.6%) 84,102 (89.5%)
                    (H1N1)pdm09 10 (90.9%) 44,604 (53.0%)
                    H3N2 1 (9.1%) 39,419 (46.9%)
                    H3N2v 0 0
                    H5* 0 79 (0.1%)
                    Subtyping not performed 2 (15.4%) 9,844 (10.5%)
                    Influenza B 2 (13.3%) 5,907 (5.9%)
                    Lineage testing performed 1 (50.0%) 3,308 (56.0%)
                    Yamagata lineage 0 0
                    Victoria lineage 1 (100%) 3,308 (100%)
                    Lineage not performed 1 (50.0%) 2,599 (44.0%)
                    *These data reflect specimens tested, and the number determined to be positive for influenza viruses at the public health labs (specimens tested is not the same as cases). The data do not reflect specimens tested only at CDC and could include more than one specimen tested per person. The guidance for avian influenza A(H5) virus testing recommends testing both a conjunctival and respiratory swab for people with conjunctivitis which has resulted in more specimens testing positive for avian influenza A(H5) virus than the number of human A(H5) cases. For more information on the number of people infected with avian influenza A(H5) viruses, please visit the "How CDC is monitoring influenza data among people to better understand the current avian influenza A (H5N1) situation"

                    When an influenza virus that normally circulates in swine (but not people) is detected in a person, it is called a "variant" influenza virus. Most human infections with variant influenza viruses occur following exposure to swine, but human-to-human transmission can occur. It is important to note that in most cases, variant influenza viruses have not shown the ability to spread easily and sustainably from human-to-human.



                    *This graph reflects the number of specimens tested and the number determined to be positive for influenza viruses at the public health lab (specimens tested is not the same as cases). It does not reflect specimens tested only at CDC and could include more than one specimen tested per person. Specimens tested as part of routine influenza surveillance as well as those tested as part of targeted testing for people exposed to avian influenza A(H5) are included.

                    Additional virologic surveillance information for current and past seasons:

                    Surveillance Methods | FluView Interactive: National, Regional, and State Data or Age Data

                    Novel Influenza A Virus Infections


                    No confirmed human infections with influenza A(H5) virus were reported to CDC this week. To date, human-to-human transmission of avian influenza A(H5) virus (H5 bird flu) has not been identified in the United States.

                    The CSTE position statement, which includes updated case definitions for confirmed, probable, and suspected cases is available at http://www.cste.org/resource/resmgr/...nfluenza_A.pdf.

                    An up-to-date human case summary during the current outbreak by state and exposure source is available at www.cdc.gov/bird-flu/situation-summary/index.html.

                    Information about avian influenza is available at https://www.cdc.gov/flu/avianflu/index.htm.

                    A(H5N1) virus interim recommendations for Prevention, Monitoring, and Public Health Investigations are available at https://www.cdc.gov/bird-flu/prevent...endations.html.

                    The latest case reports on avian influenza outbreaks in wild birds, commercial poultry, backyard or hobbyist flocks, and mammals in the United States are available from the USDA at https://www.aphis.usda.gov/h5n1-hpai#detections-hpai.

                    Additional information regarding human infections with novel influenza A viruses:

                    Surveillance Methods | FluView Interactive
                    Outpatient and Emergency Department Illness Surveillance

                    Outpatient Respiratory Illness Visits


                    The U.S. Outpatient Influenza-like Illness Surveillance Network (ILINet) monitors outpatient visits for respiratory illness referred to as influenza-like illness [ILI (fever plus cough or sore throat)], not laboratory-confirmed influenza, and may capture respiratory illness visits due to infection with any pathogen that can present with similar symptoms, including influenza, SARS-CoV-2, and RSV. Therefore, it is important to evaluate syndromic surveillance data, including that from ILINet, in the context of other sources of surveillance data to obtain a complete and accurate picture of influenza, SARS-CoV-2, and other respiratory virus activity.

                    Nationally, during Week 33, 1.2% of patient visits reported through ILINet were due to respiratory illness that included fever plus a cough or sore throat, also referred to as ILI. Multiple respiratory viruses are co-circulating, and the relative contribution of influenza virus infection to ILI varies by location.

                    Outpatient Respiratory Illness Visits by Age Group


                    More than 70% of ILINet participants provide both the number of patient visits for respiratory illness and the total number of patient visits for the week broken out by age group. Data from this subset of providers are used to calculate the percentages of patient visits for respiratory illness by age group.

                    During Week 33, the percentage of visits for respiratory illness reported in ILINet was 3.6% among those 0-4 years, 1.7% among those 5-24 years, 1.1% among those 25-49 years, 0.7% among those 50-64 years, and 0.5% among those 65 years and older.

                    Outpatient Respiratory Illness Activity Map


                    Data collected in ILINet are used to produce a measure of ILI activity* by state/jurisdiction and Core Based Statistical Areas (CBSA).
                    Week 33
                    (Week ending
                    Aug. 16, 2025)
                    Week 32
                    (Week ending
                    Aug. 9, 2025)
                    Week 33
                    (Week ending
                    Aug. 16, 2025)
                    Week 32
                    (Week ending
                    Aug. 9, 2025)
                    Very High 0 0 0 0
                    High 0 0 0 0
                    Moderate 0 0 0 0
                    Low 0 0 6 2
                    Minimal 55 54 678 693
                    Insufficient Data 0 1 245 234

                    *Data collected in ILINet may disproportionally represent certain populations within a jurisdiction or CBSA, and therefore, may not accurately depict the full picture of influenza activity for the entire jurisdiction or CBSA. Differences in the data presented here by CDC and independently by some health departments likely represent differing levels of data completeness with data presented by the health department likely being the more complete.

                    Additional information about medically attended visits for ILI for current and past seasons:

                    Surveillance Methods | FluView Interactive: National, Regional, and State Data or ILI Activity Map

                    National Syndromic Surveillance System (NSSP)


                    The overall percentage of emergency department (ED) visits with a discharge diagnosis of influenza reported in NSSP was 0.1% during Week 33. The percentage of visits was 0.3% among those 0-4 years, and 0.1% among those 5-17 years, 18-64 years, and 65 years and older. RegionNationalRegion 1Region 2Region 3Region 4Region 5Region 6Region 7Region 8Region 9Region 10
                    Season2023-2024 & 2024-20252022-2023 Skip Over Chart Container
                    2.0%4.0%6.0%8.0%10.0%12.0%14.0%16.0%Percent of Emergency Department Visits for InfluenzaWeek 41 of 2023Week 45 of 2023Week 49 of 2023Week 1 of 2024Week 5 of 2024Week 9 of 2024Week 13 of 2024Week 17 of 2024Week 21 of 2024Week 25 of 2024Week 29 of 2024Week 33 of 2024Week 37 of 2024Week 41 of 2024Week 45 of 2024Week 49 of 2024Week 1 of 2025Week 5 of 2025Week 9 of 2025Week 13 of 2025Week 17 of 2025Week 21 of 2025Week 25 of 2025Week 29 of 2025Week 33 of 2025

                    Age Group

                    Skip Data Table
                    Data Table Download Data (CSV) Skipped data table.

                    Additional information about emergency department visits for flu for current and past seasons:‎‎‎

                    Surveillance Methods | Emergency Department Visits for COVID-19, flu, and RSV
                    Hospitalization surveillance

                    FluSurv-Net


                    The Influenza Hospitalization Surveillance Network (FluSurv-NET) conducts population-based surveillance for laboratory-confirmed influenza-related hospitalizations in select counties in 14 states and represents approximately 9% of the U.S. population. FluSurv-NET hospitalization data are preliminary. Patients admitted for laboratory-confirmed influenza-related hospitalization after April 30, 2025, will not be included in FluSurv-NET for the 2024-2025 season. Data on patients admitted through April 30, 2025, will continue to be updated on FluView Interactive as additional information is received.

                    Additional FluSurv-NET hospitalization surveillance information for current and past seasons and additional age groups:

                    Surveillance Methods | FluView Interactive: Rates by Age, Sex, and Race/Ethnicity or Data on Patient Characteristics | RESP-NET Interactive

                    National Healthcare Safety Network (NHSN) Hospital Respiratory Data


                    Hospitals report to NHSN the weekly number of patients with laboratory-confirmed influenza who were admitted to the hospital. Nationally, during Week 33, 738 (0.2 per 100,000 population) laboratory-confirmed influenza-associated hospitalizations were reported. When examining rates by age, the highest hospital admission rate per 100,000 population was among those 65 years and older (0.7), followed by those 50-64 years and 0-4 years (0.2 each).

                    Additional NHSN Hospital Respiratory Data information:

                    Surveillance Methods | Additional Data | FluView Interactive
                    Mortality surveillance

                    National Center for Health Statistics (NCHS) Mortality Surveillance


                    Based on NCHS mortality surveillance data available on August 21, 2025, 0.03% of the deaths that occurred during the week ending August 16, 2025 (Week 33) were due to influenza. The data presented are preliminary and may change as more data are received and processed.

                    Additional pneumonia, influenza and COVID-19 mortality surveillance information for current and past seasons:

                    Surveillance Methods | FluView Interactive

                    Influenza-Associated Pediatric Mortality


                    Five influenza-associated pediatric deaths occurring during the 2024-2025 season were reported to CDC during Week 33. The deaths occurred between Week 4 (the week ending January 25, 2025) and Week 21 (the week ending May 24, 2025). A total of 275 influenza-associated pediatric deaths occurring during the 2024-2025 season have been reported to CDC. This is the highest number of pediatric deaths reported in any non-pandemic influenza season since the condition became reportable in 2004.

                    Among children who were eligible for influenza vaccination and with known vaccine status, 90% of reported pediatric deaths this season (compared to 82% during the 2023-2024 season) have occurred in children who were not fully vaccinated against influenza.

                    Additional pediatric mortality surveillance information for current and past seasons:

                    Surveillance Methods | FluView Interactive
                    All data in this report are preliminary and may change as more reports are received.

                    A description of the CDC influenza surveillance system, including methodology and detailed descriptions of each data component, is available on the surveillance methods page.1

                    Additional information on the current and previous influenza seasons for each surveillance component are available on FluView Interactive.

                    Additional National and International Influenza Surveillance Information

                    Additional surveillance information


                    FluView Interactive: FluView includes enhanced web-based interactive applications that can provide dynamic visuals of the influenza data collected and analyzed by CDC. These FluView Interactive applications allow people to create customized, visual interpretations of influenza data, as well as make comparisons across flu seasons, regions, age groups and a variety of other demographics.

                    National Institute for Occupational Safety and Health: Monthly surveillance data on the prevalence of health-related workplace absenteeism among full-time workers in the United States are available from NIOSH.

                    Comment


                    • #40
                      Weekly US Influenza Surveillance Report: Key Updates for Week 34, ending August 23, 2025

                      For Everyone
                      Aug. 29, 2025

                      Key points


                      Seasonal influenza activity is low.
                      U.S. virologic surveillance

                      Clinical Laboratories


                      The results of tests performed by clinical laboratories nationwide are summarized below. Data from clinical laboratories (the percentage of specimens tested that are positive for influenza) are used to monitor whether influenza activity is increasing or decreasing. Nationally, during Week 34, the percentage of respiratory specimens testing positive for influenza virus in clinical laboratories was 0.4%.
                      No. of specimens tested 32,734 3,925,834
                      No. of positive specimens (%) 123 (0.4%) 489,328 (12.5%)
                      Positive specimens by type
                      Influenza A 101 (82.1%) 434,804 (88.9%)
                      Influenza B 22 (17.9%) 54,524 (11.1%)
                      View Larger Influenza Positive Tests Reported to CDC by Clinical Laboratories, National Summary, 2024-25 Season, week ending Aug. 23, 2025
                      View Chart Data

                      Public Health Laboratories


                      The results of tests performed by public health laboratories nationwide are summarized below. Data from public health laboratories are used to monitor the proportion of circulating viruses that belong to each influenza virus type/subtype/lineage. Viruses known to be associated with recent live attenuated influenza vaccine (LAIV) receipt or found upon further testing to be a vaccine virus are not included as they are not circulating influenza viruses.
                      No. of specimens tested 353 154,714
                      No. of positive specimens 16 99,931
                      Positive specimens by type/subtype
                      Influenza A 15 (93.8%) 94,004 (94.1%)
                      Subtyping Performed 12 (80.0%) 84,159 (89.5%)
                      (H1N1)pdm09 11 (91.7%) 44,646 (53.0%)
                      H3N2 1 (8.3%) 39,434 (46.9%)
                      H3N2v 0 0
                      H5 0 79 (0.1%)
                      Subtyping not performed 3 (20.0%) 9,845 (10.5%)
                      Influenza B 1 (6.3%) 5,927 (5.9%)
                      Lineage testing performed 0 3,323 (56.1%)
                      Yamagata lineage 0 0
                      Victoria lineage 0 3,323 (100%)
                      Lineage not performed 1 (100%) 2,604 (43.9%)
                      *These data reflect specimens tested, and the number determined to be positive for influenza viruses at the public health labs (specimens tested is not the same as cases). The data do not reflect specimens tested only at CDC and could include more than one specimen tested per person. The guidance for avian influenza A(H5) virus testing recommends testing both a conjunctival and respiratory swab for people with conjunctivitis which has resulted in more specimens testing positive for avian influenza A(H5) virus than the number of human A(H5) cases. For more information on the number of people infected with avian influenza A(H5) viruses, please visit the "How CDC is monitoring influenza data among people to better understand the current avian influenza A (H5N1) situation"

                      When an influenza virus that normally circulates in swine (but not people) is detected in a person, it is called a "variant" influenza virus. Most human infections with variant influenza viruses occur following exposure to swine, but human-to-human transmission can occur. It is important to note that in most cases, variant influenza viruses have not shown the ability to spread easily and sustainably from human-to-human. View Larger This graph reflects the number of specimens tested and the number determined to be positive for influenza viruses at the public health lab (specimens tested is not the same as cases). It does not reflect specimens tested only at CDC and could include... Show More
                      View Chart Data

                      Additional virologic surveillance information for current and past seasons:

                      Surveillance Methods | FluView Interactive: National, Regional, and State Data or Age Data

                      Novel Influenza A Virus Infections


                      No confirmed human infections with influenza A(H5) virus were reported to CDC this week. To date, human-to-human transmission of avian influenza A(H5) virus (H5 bird flu) has not been identified in the United States.

                      The CSTE position statement, which includes updated case definitions for confirmed, probable, and suspected cases is available at http://www.cste.org/resource/resmgr/...nfluenza_A.pdf.

                      An up-to-date human case summary during the current outbreak by state and exposure source is available at www.cdc.gov/bird-flu/situation-summary/index.html.

                      Information about avian influenza is available at https://www.cdc.gov/flu/avianflu/index.htm.

                      A(H5N1) virus interim recommendations for Prevention, Monitoring, and Public Health Investigations are available at https://www.cdc.gov/bird-flu/prevent...endations.html.

                      The latest case reports on avian influenza outbreaks in wild birds, commercial poultry, backyard or hobbyist flocks, and mammals in the United States are available from the USDA at https://www.aphis.usda.gov/h5n1-hpai#detections-hpai.

                      Additional information regarding human infections with novel influenza A viruses:

                      Surveillance Methods | FluView Interactive
                      Outpatient and Emergency Department Illness Surveillance

                      Outpatient Respiratory Illness Visits


                      The U.S. Outpatient Influenza-like Illness Surveillance Network (ILINet) monitors outpatient visits for respiratory illness referred to as influenza-like illness [ILI (fever plus cough or sore throat)], not laboratory-confirmed influenza, and may capture respiratory illness visits due to infection with any pathogen that can present with similar symptoms, including influenza, SARS-CoV-2, and RSV. Therefore, it is important to evaluate syndromic surveillance data, including that from ILINet, in the context of other sources of surveillance data to obtain a complete and accurate picture of influenza, SARS-CoV-2, and other respiratory virus activity.

                      Nationally, during Week 34, 1.4% of patient visits reported through ILINet were due to respiratory illness that included fever plus a cough or sore throat, also referred to as ILI. Multiple respiratory viruses are co-circulating, and the relative contribution of influenza virus infection to ILI varies by location. View Larger Percentage of Outpatient Visits for Respiratory Illness Reported by. The U.S. Outpatient Influenza-like Illness Surveillance Network (ILINet)

                      Outpatient Respiratory Illness Visits by Age Group


                      More than 70% of ILINet participants provide both the number of patient visits for respiratory illness and the total number of patient visits for the week broken out by age group. Data from this subset of providers are used to calculate the percentages of patient visits for respiratory illness by age group.

                      During Week 34, the percentage of visits for respiratory illness reported in ILINet was 4.4% among those 0-4 years, 2.3% among those 5-24 years, 1.2% among those 25-49 years, 0.8% among those 50-64 years, and 0.6% among those 65 years and older.

                      Outpatient Respiratory Illness Activity Map


                      Data collected in ILINet are used to produce a measure of ILI activity* by state/jurisdiction and Core Based Statistical Areas (CBSA).
                      Week 34
                      (Week ending
                      Aug. 23, 2025)
                      Week 33
                      (Week ending
                      Aug. 16, 2025)
                      Week 34
                      (Week ending
                      Aug. 23, 2025)
                      Week 33
                      (Week ending
                      Aug. 16, 2025)
                      Very High 0 0 0 0
                      High 0 0 1 0
                      Moderate 0 0 6 0
                      Low 0 0 22 6
                      Minimal 55 55 655 678
                      Insufficient Data 0 0 245 245

                      *Data collected in ILINet may disproportionally represent certain populations within a jurisdiction or CBSA, and therefore, may not accurately depict the full picture of influenza activity for the entire jurisdiction or CBSA. Differences in the data presented here by CDC and independently by some health departments likely represent differing levels of data completeness with data presented by the health department likely being the more complete.

                      Additional information about medically attended visits for ILI for current and past seasons:

                      Surveillance Methods | FluView Interactive: National, Regional, and State Data or ILI Activity Map

                      National Syndromic Surveillance System (NSSP)


                      The overall percentage of emergency department (ED) visits with a discharge diagnosis of influenza reported in NSSP was 0.1% during Week 34. The percentage of visits was 0.3% among those 0-4 and 5-17 years, and 0.1% among those 18-64 years and 65 years and older. RegionNationalRegion 1Region 2Region 3Region 4Region 5Region 6Region 7Region 8Region 9Region 10
                      Season2023-2024 & 2024-20252022-2023 Skip Over Chart Container
                      2.0%4.0%6.0%8.0%10.0%12.0%14.0%16.0%Percent of Emergency Department Visits for InfluenzaWeek 42 of 2023Week 46 of 2023Week 50 of 2023Week 2 of 2024Week 6 of 2024Week 10 of 2024Week 14 of 2024Week 18 of 2024Week 22 of 2024Week 26 of 2024Week 30 of 2024Week 34 of 2024Week 38 of 2024Week 42 of 2024Week 46 of 2024Week 50 of 2024Week 2 of 2025Week 6 of 2025Week 10 of 2025Week 14 of 2025Week 18 of 2025Week 22 of 2025Week 26 of 2025Week 30 of 2025Week 34 of 2025

                      Age Group

                      Skip Data Table
                      Data Table Download Data (CSV)
                      Skipped data table.

                      Additional information about emergency department visits for flu for current and past seasons:‎‎‎

                      Surveillance Methods | Emergency Department Visits for COVID-19, flu, and RSV
                      Hospitalization surveillance

                      FluSurv-Net


                      The Influenza Hospitalization Surveillance Network (FluSurv-NET) conducts population-based surveillance for laboratory-confirmed influenza-related hospitalizations in select counties in 14 states and represents approximately 9% of the U.S. population. FluSurv-NET hospitalization data are preliminary. Patients admitted for laboratory-confirmed influenza-related hospitalization after April 30, 2025, will not be included in FluSurv-NET for the 2024-2025 season. Data on patients admitted through April 30, 2025, will continue to be updated on FluView Interactive as additional information is received.

                      Additional FluSurv-NET hospitalization surveillance information for current and past seasons and additional age groups:

                      Surveillance Methods | FluView Interactive: Rates by Age, Sex, and Race/Ethnicity or Data on Patient Characteristics | RESP-NET Interactive

                      National Healthcare Safety Network (NHSN) Hospital Respiratory Data


                      Hospitals report to NHSN the weekly number of patients with laboratory-confirmed influenza who were admitted to the hospital. Nationally, during Week 34, 725 (0.2 per 100,000 population) laboratory-confirmed influenza-associated hospitalizations were reported. When examining rates by age, the highest hospital admission rate per 100,000 population was among those 65 years and older (0.7), followed by those 50-64 years and 0-4 years (0.2 each).

                      Additional NHSN Hospital Respiratory Data information:

                      Surveillance Methods | Additional Data | FluView Interactive
                      Mortality surveillance

                      National Center for Health Statistics (NCHS) Mortality Surveillance


                      Based on NCHS mortality surveillance data available on August 28, 2025, 0.03% of the deaths that occurred during the week ending August 23, 2025 (Week 34) were due to influenza. The data presented are preliminary and may change as more data are received and processed.

                      Additional pneumonia, influenza and COVID-19 mortality surveillance information for current and past seasons:

                      Surveillance Methods | FluView Interactive

                      Influenza-Associated Pediatric Mortality


                      Three influenza-associated pediatric deaths occurring during the 2024-2025 season were reported to CDC during Week 34. The deaths occurred during weeks 7, 13 and 23 (the weeks ending February 15, March 29, and June 7, 2025, respectively). A total of 278 influenza-associated pediatric deaths occurring during the 2024-2025 season have been reported to CDC. This is the highest number of pediatric deaths reported in any non-pandemic influenza season since the condition became reportable in 2004. Among children who were eligible for influenza vaccination and with known vaccine status, 90% of reported pediatric deaths this season (compared to 82% during the 2023-2024 season) have occurred in children who were not fully vaccinated against influenza.

                      One death that occurred during the 2023-2024 season during week 4 (the week ending January 27, 2024) was also reported. This brings the total number of pediatric deaths for last season to 210.

                      Additional pediatric mortality surveillance information for current and past seasons:

                      Surveillance Methods | FluView Interactive
                      All data in this report are preliminary and may change as more reports are received.

                      A description of the CDC influenza surveillance system, including methodology and detailed descriptions of each data component, is available on the surveillance methods page.1

                      Additional information on the current and previous influenza seasons for each surveillance component are available on FluView Interactive.

                      Additional National and International Influenza Surveillance Information

                      Additional surveillance information


                      FluView Interactive: FluView includes enhanced web-based interactive applications that can provide dynamic visuals of the influenza data collected and analyzed by CDC. These FluView Interactive applications allow people to create customized, visual interpretations of influenza data, as well as make comparisons across flu seasons, regions, age groups and a variety of other demographics.

                      National Institute for Occupational Safety and Health: Monthly surveillance data on the prevalence of health-related workplace absenteeism among full-time workers in the United States are available from NIOSH.

                      Comment


                      • #41
                        Weekly US Influenza Surveillance Report: Key Updates for Week 35, ending August 30, 2025

                        For Everyone
                        Sept. 5, 2025

                        Key points


                        Seasonal influenza activity is low.
                        U.S. virologic surveillance

                        Clinical Laboratories


                        The results of tests performed by clinical laboratories nationwide are summarized below. Data from clinical laboratories (the percentage of specimens tested that are positive for influenza) are used to monitor whether influenza activity is increasing or decreasing. Nationally, during Week 35, the percentage of respiratory specimens testing positive for influenza virus in clinical laboratories was 0.4%.
                        No. of specimens tested 39,531 3,978,954
                        No. of positive specimens (%) 163 (0.4%) 489,579 (12.3%)
                        Positive specimens by type
                        Influenza A 130 (79.8%) 434,985 (88.8%)
                        Influenza B 33 (20.2%) 54,594 (11.2%)
                        Public Health Laboratories


                        The results of tests performed by public health laboratories nationwide are summarized below. Data from public health laboratories are used to monitor the proportion of circulating viruses that belong to each influenza virus type/subtype/lineage. Viruses known to be associated with recent live attenuated influenza vaccine (LAIV) receipt or found upon further testing to be a vaccine virus are not included as they are not circulating influenza viruses.
                        No. of specimens tested 328 155,297
                        No. of positive specimens 22 100,015
                        Positive specimens by type/subtype
                        Influenza A 22 (100%) 94,078 (94.1%)
                        Subtyping Performed 18 (81.8%) 84,339 (89.6%)
                        (H1N1)pdm09 13 (72.2%) 44,733 (53.0%)
                        H3N2 5 (27.8%) 39,527 (46.9%)
                        H3N2v 0 0
                        H5* 0 79 (0.1%)
                        Subtyping not performed 4 (18.2%) 9,739 (10.4%)
                        Influenza B 0 5,937 (5.9%)
                        Lineage testing performed 0 3,297 (55.5%)
                        Yamagata lineage 0 0
                        Victoria lineage 0 3,297 (100%)
                        Lineage not performed 0 2,640 (44.5%)
                        *These data reflect specimens tested, and the number determined to be positive for influenza viruses at the public health labs (specimens tested is not the same as cases). The data do not reflect specimens tested only at CDC and could include more than one specimen tested per person. The guidance for avian influenza A(H5) virus testing recommends testing both a conjunctival and respiratory swab for people with conjunctivitis which has resulted in more specimens testing positive for avian influenza A(H5) virus than the number of human A(H5) cases. For more information on the number of people infected with avian influenza A(H5) viruses, please visit the "How CDC is monitoring influenza data among people to better understand the current avian influenza A (H5N1) situation"

                        When an influenza virus that normally circulates in swine (but not people) is detected in a person, it is called a "variant" influenza virus. Most human infections with variant influenza viruses occur following exposure to swine, but human-to-human transmission can occur. It is important to note that in most cases, variant influenza viruses have not shown the ability to spread easily and sustainably from human-to-human.



                        *This graph reflects the number of specimens tested and the number determined to be positive for influenza viruses at the public health lab (specimens tested is not the same as cases). It does not reflect specimens tested only at CDC and could include more than one specimen tested per person. Specimens tested as part of routine influenza surveillance as well as those tested as part of targeted testing for people exposed to avian influenza A(H5) are included.

                        Additional virologic surveillance information for current and past seasons:

                        Surveillance Methods | FluView Interactive: National, Regional, and State Data or Age Data

                        Novel Influenza A Virus Infections


                        No confirmed human infections with influenza A(H5) virus were reported to CDC this week. To date, human-to-human transmission of avian influenza A(H5) virus (H5 bird flu) has not been identified in the United States.

                        The CSTE position statement, which includes updated case definitions for confirmed, probable, and suspected cases is available at http://www.cste.org/resource/resmgr/...nfluenza_A.pdf.

                        An up-to-date human case summary during the current outbreak by state and exposure source is available at www.cdc.gov/bird-flu/situation-summary/index.html.

                        Information about avian influenza is available at https://www.cdc.gov/flu/avianflu/index.htm.

                        A(H5N1) virus interim recommendations for Prevention, Monitoring, and Public Health Investigations are available at https://www.cdc.gov/bird-flu/prevent...endations.html.

                        The latest case reports on avian influenza outbreaks in wild birds, commercial poultry, backyard or hobbyist flocks, and mammals in the United States are available from the USDA at https://www.aphis.usda.gov/h5n1-hpai#detections-hpai.

                        Additional information regarding human infections with novel influenza A viruses:

                        Surveillance Methods | FluView Interactive

                        Outpatient and Emergency Department Illness Surveillance

                        Outpatient Respiratory Illness Visits


                        The U.S. Outpatient Influenza-like Illness Surveillance Network (ILINet) monitors outpatient visits for respiratory illness referred to as influenza-like illness [ILI (fever plus cough or sore throat)], not laboratory-confirmed influenza, and may capture respiratory illness visits due to infection with any pathogen that can present with similar symptoms, including influenza, SARS-CoV-2, and RSV. Therefore, it is important to evaluate syndromic surveillance data, including that from ILINet, in the context of other sources of surveillance data to obtain a complete and accurate picture of influenza, SARS-CoV-2, and other respiratory virus activity.

                        Nationally, during Week 35, 1.8% of patient visits reported through ILINet were due to respiratory illness that included fever plus a cough or sore throat, also referred to as ILI. Multiple respiratory viruses are co-circulating, and the current relative contribution of influenza virus infection to ILI varies by location. Although ILI activity is rising, other surveillance indicators show this increase is not attributable to influenza, but other respiratory illness pathogens.

                        Outpatient Respiratory Illness Visits by Age Group


                        More than 70% of ILINet participants provide both the number of patient visits for respiratory illness and the total number of patient visits for the week broken out by age group. Data from this subset of providers are used to calculate the percentages of patient visits for respiratory illness by age group.

                        During Week 35, the percentage of visits for respiratory illness reported in ILINet was 5.0% among those 0-4 years, 2.8% among those 5-24 years, 1.5% among those 25-49 years, 0.9% among those 50-64 years, and 0.7% among those 65 years and older.

                        Outpatient Respiratory Illness Activity Map


                        Data collected in ILINet are used to produce a measure of ILI activity* by state/jurisdiction and Core Based Statistical Areas (CBSA).
                        Week 35
                        (Week ending
                        Aug. 30, 2025)
                        Week 34
                        (Week ending
                        Aug. 23, 2025)
                        Week 35
                        (Week ending
                        Aug. 30, 2025)
                        Week 34
                        (Week ending
                        Aug. 23, 2025)
                        Very High 0 0 0 0
                        High 0 0 4 1
                        Moderate 0 0 7 6
                        Low 2 0 42 22
                        Minimal 51 55 590 656
                        Insufficient Data 2 0 286 244

                        *Data collected in ILINet may disproportionally represent certain populations within a jurisdiction or CBSA, and therefore, may not accurately depict the full picture of influenza activity for the entire jurisdiction or CBSA. Differences in the data presented here by CDC and independently by some health departments likely represent differing levels of data completeness with data presented by the health department likely being the more complete.

                        Additional information about medically attended visits for ILI for current and past seasons:

                        Surveillance Methods | FluView Interactive: National, Regional, and State Data or ILI Activity Map

                        National Syndromic Surveillance System (NSSP)


                        The overall percentage of emergency department (ED) visits with a discharge diagnosis of influenza reported in NSSP was 0.1% during Week 35. The percentage of visits was 0.4% among those 0-4 years, 0.3% among those 5-17 years, and 0.1% among those 18-64 years and 65 years and older. RegionNationalRegion 1Region 2Region 3Region 4Region 5Region 6Region 7Region 8Region 9Region 10
                        Season2023-2024 & 2024-20252022-2023 Skip Over Chart Container
                        2.0%4.0%6.0%8.0%10.0%12.0%14.0%16.0%Percent of Emergency Department Visits for InfluenzaWeek 43 of 2023Week 47 of 2023Week 51 of 2023Week 3 of 2024Week 7 of 2024Week 11 of 2024Week 15 of 2024Week 19 of 2024Week 23 of 2024Week 27 of 2024Week 31 of 2024Week 35 of 2024Week 39 of 2024Week 43 of 2024Week 47 of 2024Week 51 of 2024Week 3 of 2025Week 7 of 2025Week 11 of 2025Week 15 of 2025Week 19 of 2025Week 23 of 2025Week 27 of 2025Week 31 of 2025Week 35 of 2025

                        Age Group

                        Skip Data Table
                        Data Table Download Data (CSV)
                        Skipped data table.

                        Additional information about emergency department visits for flu for current and past seasons:‎‎‎

                        Surveillance Methods | Emergency Department Visits for COVID-19, flu, and RSV
                        Hospitalization surveillance

                        FluSurv-Net


                        The Influenza Hospitalization Surveillance Network (FluSurv-NET) conducts population-based surveillance for laboratory-confirmed influenza-related hospitalizations in select counties in 14 states and represents approximately 9% of the U.S. population. FluSurv-NET hospitalization data are preliminary. Patients admitted for laboratory-confirmed influenza-related hospitalization after April 30, 2025, will not be included in FluSurv-NET for the 2024-2025 season. Data on patients admitted through April 30, 2025, will continue to be updated on FluView Interactive as additional information is received.

                        Additional FluSurv-NET hospitalization surveillance information for current and past seasons and additional age groups:

                        Surveillance Methods | FluView Interactive: Rates by Age, Sex, and Race/Ethnicity or Data on Patient Characteristics | RESP-NET Interactive

                        National Healthcare Safety Network (NHSN) Hospital Respiratory Data


                        Hospitals report to NHSN the weekly number of patients with laboratory-confirmed influenza who were admitted to the hospital. Nationally, during Week 35, 812 (0.2 per 100,000 population) laboratory-confirmed influenza-associated hospitalizations were reported. When examining rates by age, the highest hospital admission rate per 100,000 population was among those 65 years and older (0.8), followed by those 0-4 years (0.3), and 50-64 years (0.2).

                        Additional NHSN Hospital Respiratory Data information:

                        Surveillance Methods | Additional Data | FluView Interactive

                        Mortality surveillance

                        National Center for Health Statistics (NCHS) Mortality Surveillance


                        Based on NCHS mortality surveillance data available on September 4, 2025, 0.02% of the deaths that occurred during the week ending August 30, 2025 (Week 35) were due to influenza. The data presented are preliminary and may change as more data are received and processed.

                        Additional pneumonia, influenza and COVID-19 mortality surveillance information for current and past seasons:

                        Surveillance Methods | FluView Interactive

                        Influenza-Associated Pediatric Mortality


                        One influenza-associated pediatric death that occurred during Week 34 (the week ending August 23, 2025) of the 2024-2025 season was reported to CDC during Week 35. A total of 279 influenza-associated pediatric deaths occurring during the 2024-2025 season have been reported to CDC. This is the highest number of pediatric deaths reported in any non-pandemic influenza season since the condition became reportable in 2004.

                        Among children who were eligible for influenza vaccination and with known vaccine status, 90% of reported pediatric deaths this season (compared to 82% during the 2023-2024 season) have occurred in children who were not fully vaccinated against influenza.

                        Additional pediatric mortality surveillance information for current and past seasons:

                        Surveillance Methods | FluView Interactive
                        All data in this report are preliminary and may change as more reports are received.

                        A description of the CDC influenza surveillance system, including methodology and detailed descriptions of each data component, is available on the surveillance methods page.1

                        Additional information on the current and previous influenza seasons for each surveillance component are available on FluView Interactive.

                        Additional National and International Influenza Surveillance Information

                        Additional surveillance information


                        FluView Interactive: FluView includes enhanced web-based interactive applications that can provide dynamic visuals of the influenza data collected and analyzed by CDC. These FluView Interactive applications allow people to create customized, visual interpretations of influenza data, as well as make comparisons across flu seasons, regions, age groups and a variety of other demographics.

                        National Institute for Occupational Safety and Health: Monthly surveillance data on the prevalence of health-related workplace absenteeism among full-time workers in the United States are available from NIOSH.

                        Comment


                        • #42
                          Weekly US Influenza Surveillance Report: Key Updates for Week 36, ending September 6, 2025

                          For Everyone
                          Sept. 12, 2025 Key points


                          Seasonal influenza activity is low.
                          U.S. virologic surveillance

                          Clinical Laboratories


                          The results of tests performed by clinical laboratories nationwide are summarized below. Data from clinical laboratories (the percentage of specimens tested that are positive for influenza) are used to monitor whether influenza activity is increasing or decreasing. Nationally, during Week 36, the percentage of respiratory specimens testing positive for influenza virus in clinical laboratories was 0.4%.
                          No. of specimens tested 36,735 4,023,831
                          No. of positive specimens (%) 142 (0.4%) 489,750 (12.2%)
                          Positive specimens by type
                          Influenza A 125 (88.0%) 435,132 (88.8%)
                          Influenza B 17 (12.0%) 54,618 (11.2%)
                          Public Health Laboratories


                          The results of tests performed by public health laboratories nationwide are summarized below. Data from public health laboratories are used to monitor the proportion of circulating viruses that belong to each influenza virus type/subtype/lineage. Viruses known to be associated with recent live attenuated influenza vaccine (LAIV) receipt or found upon further testing to be a vaccine virus are not included as they are not circulating influenza viruses.
                          No. of specimens tested 390 156,491
                          No. of positive specimens 21 100,279
                          Positive specimens by type/subtype
                          Influenza A 19 (90.5%) 94,287 (94.0%)
                          Subtyping Performed 11 (57.9%) 84,608 (89.7%)
                          (H1N1)pdm09 9 (81.8%) 44,911 (53.1%)
                          H3N2 2 (18.2%) 39,618 (46.8%)
                          H3N2v 0 0
                          H5* 0 79 (0.1%)
                          Subtyping not performed 8 (42.1%) 9,679 (10.3%)
                          Influenza B 2 (9.5%) 5,992 (6.0%)
                          Lineage testing performed 0 3,301 (55.1%)
                          Yamagata lineage 0 0
                          Victoria lineage 0 3,301 (100%)
                          Lineage not performed 2 (100%) 2,691 (44.9%)
                          *These data reflect specimens tested, and the number determined to be positive for influenza viruses at the public health labs (specimens tested is not the same as cases). The data do not reflect specimens tested only at CDC and could include more than one specimen tested per person. The guidance for avian influenza A(H5) virus testing recommends testing both a conjunctival and respiratory swab for people with conjunctivitis which has resulted in more specimens testing positive for avian influenza A(H5) virus than the number of human A(H5) cases. For more information on the number of people infected with avian influenza A(H5) viruses, please visit the "How CDC is monitoring influenza data among people to better understand the current avian influenza A (H5N1) situation"

                          When an influenza virus that normally circulates in swine (but not people) is detected in a person, it is called a "variant" influenza virus. Most human infections with variant influenza viruses occur following exposure to swine, but human-to-human transmission can occur. It is important to note that in most cases, variant influenza viruses have not shown the ability to spread easily and sustainably from human-to-human.



                          *This graph reflects the number of specimens tested and the number determined to be positive for influenza viruses at the public health lab (specimens tested is not the same as cases). It does not reflect specimens tested only at CDC and could include more than one specimen tested per person. Specimens tested as part of routine influenza surveillance as well as those tested as part of targeted testing for people exposed to avian influenza A(H5) are included.

                          Additional virologic surveillance information for current and past seasons:

                          Surveillance Methods | FluView Interactive: National, Regional, and State Data or Age Data

                          Novel Influenza A Virus Infections


                          No confirmed human infections with influenza A(H5) virus were reported to CDC this week. To date, human-to-human transmission of avian influenza A(H5) virus (H5 bird flu) has not been identified in the United States.

                          The CSTE position statement, which includes updated case definitions for confirmed, probable, and suspected cases is available at http://www.cste.org/resource/resmgr/...nfluenza_A.pdf.

                          An up-to-date human case summary during the current outbreak by state and exposure source is available at www.cdc.gov/bird-flu/situation-summary/index.html.

                          Information about avian influenza is available at https://www.cdc.gov/flu/avianflu/index.htm.

                          A(H5N1) virus interim recommendations for Prevention, Monitoring, and Public Health Investigations are available at https://www.cdc.gov/bird-flu/prevent...endations.html.

                          The latest case reports on avian influenza outbreaks in wild birds, commercial poultry, backyard or hobbyist flocks, and mammals in the United States are available from the USDA at https://www.aphis.usda.gov/h5n1-hpai#detections-hpai.

                          Additional information regarding human infections with novel influenza A viruses:

                          Surveillance Methods | FluView Interactive
                          Outpatient and Emergency Department Illness Surveillance

                          Outpatient Respiratory Illness Visits


                          The U.S. Outpatient Influenza-like Illness Surveillance Network (ILINet) monitors outpatient visits for respiratory illness referred to as influenza-like illness [ILI (fever plus cough or sore throat)], not laboratory-confirmed influenza, and may capture respiratory illness visits due to infection with any pathogen that can present with similar symptoms, including influenza, SARS-CoV-2, and RSV. Therefore, it is important to evaluate syndromic surveillance data, including that from ILINet, in the context of other sources of surveillance data to obtain a complete and accurate picture of influenza, SARS-CoV-2, and other respiratory virus activity.

                          Nationally, during Week 36, 1.8% of patient visits reported through ILINet were due to respiratory illness that included fever plus a cough or sore throat, also referred to as ILI. Multiple respiratory viruses are co-circulating, and the current relative contribution of influenza virus infection to ILI varies by location. Although ILI activity is rising, other surveillance indicators show this increase is not attributable to influenza, but other respiratory illness pathogens.

                          Outpatient Respiratory Illness Visits by Age Group


                          More than 70% of ILINet participants provide both the number of patient visits for respiratory illness and the total number of patient visits for the week broken out by age group. Data from this subset of providers are used to calculate the percentages of patient visits for respiratory illness by age group.

                          During Week 36, the percentage of visits for respiratory illness reported in ILINet was 5.2% among those 0-4 years, 2.6% among those 5-24 years, 1.5% among those 25-49 years, 1.0% among those 50-64 years, and 0.7% among those 65 years and older.

                          Outpatient Respiratory Illness Activity Map


                          Data collected in ILINet are used to produce a measure of ILI activity* by state/jurisdiction and Core Based Statistical Areas (CBSA).
                          Week 36
                          (Week ending
                          Sep. 6, 2025)
                          Week 35
                          (Week ending
                          Aug. 30, 2025)
                          Week 36
                          (Week ending
                          Sep. 6, 2025)
                          Week 35
                          (Week ending
                          Aug. 30, 2025)
                          Very High 0 0 0 0
                          High 0 0 3 4
                          Moderate 0 0 10 7
                          Low 1 2 38 42
                          Minimal 53 52 637 597
                          Insufficient Data 1 1 241 279

                          *Data collected in ILINet may disproportionally represent certain populations within a jurisdiction or CBSA, and therefore, may not accurately depict the full picture of influenza activity for the entire jurisdiction or CBSA. Differences in the data presented here by CDC and independently by some health departments likely represent differing levels of data completeness with data presented by the health department likely being the more complete.

                          Additional information about medically attended visits for ILI for current and past seasons:

                          Surveillance Methods | FluView Interactive: National, Regional, and State Data or ILI Activity Map

                          National Syndromic Surveillance System (NSSP)


                          The overall percentage of emergency department (ED) visits with a discharge diagnosis of influenza reported in NSSP was 0.2% during Week 36. The percentage of visits was 0.4% among those 0-4 years, 0.3% among those 5-17 years, and 0.1% among those 18-64 years and 65 years and older. RegionNationalRegion 1Region 2Region 3Region 4Region 5Region 6Region 7Region 8Region 9Region 10
                          Season2023-2024 & 2024-20252022-2023 Skip Over Chart Container
                          2.0%4.0%6.0%8.0%10.0%12.0%14.0%16.0%Percent of Emergency Department Visits for InfluenzaWeek 40 of 2023Week 44 of 2023Week 48 of 2023Week 52 of 2023Week 4 of 2024Week 8 of 2024Week 12 of 2024Week 16 of 2024Week 20 of 2024Week 24 of 2024Week 28 of 2024Week 32 of 2024Week 36 of 2024Week 40 of 2024Week 44 of 2024Week 48 of 2024Week 52 of 2024Week 4 of 2025Week 8 of 2025Week 12 of 2025Week 16 of 2025Week 20 of 2025Week 24 of 2025Week 28 of 2025Week 32 of 2025Week 36 of 2025

                          Age Group

                          Skip Data Table
                          Data Table Download Data (CSV)
                          Skipped data table.

                          Additional information about emergency department visits for flu for current and past seasons:‎‎‎

                          Surveillance Methods | Emergency Department Visits for COVID-19, flu, and RSV
                          Hospitalization surveillance

                          FluSurv-Net


                          The Influenza Hospitalization Surveillance Network (FluSurv-NET) conducts population-based surveillance for laboratory-confirmed influenza-related hospitalizations in select counties in 14 states and represents approximately 9% of the U.S. population. FluSurv-NET hospitalization data are preliminary. Patients admitted for laboratory-confirmed influenza-related hospitalization after April 30, 2025, will not be included in FluSurv-NET for the 2024-2025 season. Data on patients admitted through April 30, 2025, will continue to be updated on FluView Interactive as additional information is received.

                          Additional FluSurv-NET hospitalization surveillance information for current and past seasons and additional age groups:

                          Surveillance Methods | FluView Interactive: Rates by Age, Sex, and Race/Ethnicity or Data on Patient Characteristics | RESP-NET Interactive

                          National Healthcare Safety Network (NHSN) Hospital Respiratory Data


                          Hospitals report to NHSN the weekly number of patients with laboratory-confirmed influenza who were admitted to the hospital. Nationally, during Week 36, 918 (0.3 per 100,000 population) laboratory-confirmed influenza-associated hospitalizations were reported. When examining rates by age, the highest hospital admission rate per 100,000 population was among those 65 years and older (0.9), followed by those 0-4 years (0.3), and 50-64 years (0.2).

                          Additional NHSN Hospital Respiratory Data information:

                          Surveillance Methods | Additional Data | FluView Interactive
                          Mortality surveillance

                          National Center for Health Statistics (NCHS) Mortality Surveillance


                          Based on NCHS mortality surveillance data available on September 4, 2025, 0.06% of the deaths that occurred during the week ending September 6, 2025 (Week 36) were due to influenza. The data presented are preliminary and may change as more data are received and processed.

                          Additional pneumonia, influenza and COVID-19 mortality surveillance information for current and past seasons:

                          Surveillance Methods | FluView Interactive

                          Influenza-Associated Pediatric Mortality


                          One influenza-associated pediatric death that occurred during Week 5 (the week ending February 1, 2025) of the 2024-2025 season was reported to CDC during Week 36. A total of 280 influenza-associated pediatric deaths occurring during the 2024-2025 season have been reported to CDC. This is the highest number of pediatric deaths reported in any non-pandemic influenza season since the condition became reportable in 2004.

                          Among children who were eligible for influenza vaccination and with known vaccine status, 90% of reported pediatric deaths this season (compared to 82% during the 2023-2024 season) have occurred in children who were not fully vaccinated against influenza.

                          Additional pediatric mortality surveillance information for current and past seasons:

                          Surveillance Methods | FluView Interactive
                          All data in this report are preliminary and may change as more reports are received.

                          A description of the CDC influenza surveillance system, including methodology and detailed descriptions of each data component, is available on the surveillance methods page.1

                          Additional information on the current and previous influenza seasons for each surveillance component are available on FluView Interactive.

                          Additional National and International Influenza Surveillance Information

                          Additional surveillance information


                          FluView Interactive: FluView includes enhanced web-based interactive applications that can provide dynamic visuals of the influenza data collected and analyzed by CDC. These FluView Interactive applications allow people to create customized, visual interpretations of influenza data, as well as make comparisons across flu seasons, regions, age groups and a variety of other demographics.

                          National Institute for Occupational Safety and Health: Monthly surveillance data on the prevalence of health-related workplace absenteeism among full-time workers in the United States are available from NIOSH.

                          Comment


                          • #43
                            Weekly US Influenza Surveillance Report: Key Updates for Week 37, ending September 13, 2025

                            For Everyone
                            Sept. 19, 2025

                            Key points


                            Seasonal influenza activity is low.
                            U.S. virologic surveillance

                            Clinical Laboratories


                            The results of tests performed by clinical laboratories nationwide are summarized below. Data from clinical laboratories (the percentage of specimens tested that are positive for influenza) are used to monitor whether influenza activity is increasing or decreasing. Nationally, during Week 37, the percentage of respiratory specimens testing positive for influenza virus in clinical laboratories was 0.4%.
                            No. of specimens tested 41,304 4,076,717
                            No. of positive specimens (%) 145 (0.4%) 489,945 (12.0%)
                            Positive specimens by type
                            Influenza A 131 (90.3%) 435,308 (88.8%)
                            Influenza B 14 (9.7%) 54,637 (11.2%)
                            Public Health Laboratories


                            The results of tests performed by public health laboratories nationwide are summarized below. Data from public health laboratories are used to monitor the proportion of circulating viruses that belong to each influenza virus type/subtype/lineage. Viruses known to be associated with recent live attenuated influenza vaccine (LAIV) receipt or found upon further testing to be a vaccine virus are not included as they are not circulating influenza viruses.
                            No. of specimens tested 471 157,395
                            No. of positive specimens 28 100,357
                            Positive specimens by type/subtype
                            Influenza A 27 (96.4%) 94,358 (94.0%)
                            Subtyping Performed 14 (51.9%) 84,838 (89.9%)
                            (H1N1)pdm09 7 (50.0%) 45,029 (53.1%)
                            H3N2 7 (50.0%) 39,730 (46.8%)
                            H3N2v 0 0
                            H5* 0 79 (0.1%)
                            Subtyping not performed 13 (48.1%) 9,520 (10.1%)
                            Influenza B 1 (3.6%) 5,999 (6.0%)
                            Lineage testing performed 0 3,353 (55.9%)
                            Yamagata lineage 0 0
                            Victoria lineage 0 3,353 (100%)
                            Lineage not performed 1 (100%) 2,646 (44.1%)
                            *These data reflect specimens tested, and the number determined to be positive for influenza viruses at the public health labs (specimens tested is not the same as cases). The data do not reflect specimens tested only at CDC and could include more than one specimen tested per person. The guidance for avian influenza A(H5) virus testing recommends testing both a conjunctival and respiratory swab for people with conjunctivitis which has resulted in more specimens testing positive for avian influenza A(H5) virus than the number of human A(H5) cases. For more information on the number of people infected with avian influenza A(H5) viruses, please visit the "How CDC is monitoring influenza data among people to better understand the current avian influenza A (H5N1) situation"

                            When an influenza virus that normally circulates in swine (but not people) is detected in a person, it is called a "variant" influenza virus. Most human infections with variant influenza viruses occur following exposure to swine, but human-to-human transmission can occur. It is important to note that in most cases, variant influenza viruses have not shown the ability to spread easily and sustainably from human-to-human.



                            *This graph reflects the number of specimens tested and the number determined to be positive for influenza viruses at the public health lab (specimens tested is not the same as cases). It does not reflect specimens tested only at CDC and could include more than one specimen tested per person. Specimens tested as part of routine influenza surveillance as well as those tested as part of targeted testing for people exposed to avian influenza A(H5) are included.

                            Additional virologic surveillance information for current and past seasons:

                            Surveillance Methods | FluView Interactive: National, Regional, and State Data or Age Data

                            Novel Influenza A Virus Infections


                            No confirmed human infections with influenza A(H5) virus were reported to CDC this week. To date, human-to-human transmission of avian influenza A(H5) virus (H5 bird flu) has not been identified in the United States.

                            The CSTE position statement, which includes updated case definitions for confirmed, probable, and suspected cases is available at http://www.cste.org/resource/resmgr/...nfluenza_A.pdf.

                            An up-to-date human case summary during the current outbreak by state and exposure source is available at www.cdc.gov/bird-flu/situation-summary/index.html.

                            Information about avian influenza is available at https://www.cdc.gov/flu/avianflu/index.htm.

                            A(H5N1) virus interim recommendations for Prevention, Monitoring, and Public Health Investigations are available at https://www.cdc.gov/bird-flu/prevent...endations.html.

                            The latest case reports on avian influenza outbreaks in wild birds, commercial poultry, backyard or hobbyist flocks, and mammals in the United States are available from the USDA at https://www.aphis.usda.gov/h5n1-hpai#detections-hpai.

                            Additional information regarding human infections with novel influenza A viruses:

                            Surveillance Methods | FluView Interactive
                            Outpatient and Emergency Department Illness Surveillance

                            Outpatient Respiratory Illness Visits


                            The U.S. Outpatient Influenza-like Illness Surveillance Network (ILINet) monitors outpatient visits for respiratory illness referred to as influenza-like illness [ILI (fever plus cough or sore throat)], not laboratory-confirmed influenza, and may capture respiratory illness visits due to infection with any pathogen that can present with similar symptoms, including influenza, SARS-CoV-2, and RSV. Therefore, it is important to evaluate syndromic surveillance data, including that from ILINet, in the context of other sources of surveillance data to obtain a complete and accurate picture of influenza, SARS-CoV-2, and other respiratory virus activity.

                            Nationally, during Week 37, 1.7% of patient visits reported through ILINet were due to respiratory illness that included fever plus a cough or sore throat, also referred to as ILI. Multiple respiratory viruses are co-circulating, and the current relative contribution of influenza virus infection to ILI varies by location.

                            Outpatient Respiratory Illness Visits by Age Group


                            More than 70% of ILINet participants provide both the number of patient visits for respiratory illness and the total number of patient visits for the week broken out by age group. Data from this subset of providers are used to calculate the percentages of patient visits for respiratory illness by age group.

                            During Week 37, the percentage of visits for respiratory illness reported in ILINet was 5.1% among those 0-4 years, 2.5% among those 5-24 years, 1.5% among those 25-49 years, 0.9% among those 50-64 years, and 0.7% among those 65 years and older.

                            Outpatient Respiratory Illness Activity Map


                            Data collected in ILINet are used to produce a measure of ILI activity* by state/jurisdiction and Core Based Statistical Areas (CBSA).
                            Week 37
                            (Week ending
                            Sep. 13, 2025)
                            Week 36
                            (Week ending
                            Sep. 6, 2025)
                            Week 37
                            (Week ending
                            Sep. 13, 2025)
                            Week 36
                            (Week ending
                            Sep. 6, 2025)
                            Very High 0 0 0 0
                            High 0 0 3 3
                            Moderate 0 0 3 10
                            Low 0 1 25 36
                            Minimal 55 53 629 642
                            Insufficient Data 0 1 269 238

                            *Data collected in ILINet may disproportionally represent certain populations within a jurisdiction or CBSA, and therefore, may not accurately depict the full picture of influenza activity for the entire jurisdiction or CBSA. Differences in the data presented here by CDC and independently by some health departments likely represent differing levels of data completeness with data presented by the health department likely being the more complete.

                            Additional information about medically attended visits for ILI for current and past seasons:

                            Surveillance Methods | FluView Interactive: National, Regional, and State Data or ILI Activity Map

                            National Syndromic Surveillance System (NSSP)


                            The overall percentage of emergency department (ED) visits with a discharge diagnosis of influenza reported in NSSP was 0.2% during Week 37. The percentage of visits was 0.4% among those 0-4 years, 0.3% among those 5-17 years, and 0.1% among those 18-64 years and 65 years and older. RegionNationalRegion 1Region 2Region 3Region 4Region 5Region 6Region 7Region 8Region 9Region 10
                            Season2023-2024 & 2024-20252022-2023 Skip Over Chart Container
                            2.0%4.0%6.0%8.0%10.0%12.0%14.0%16.0%Percent of Emergency Department Visits for InfluenzaWeek 41 of 2023Week 45 of 2023Week 49 of 2023Week 1 of 2024Week 5 of 2024Week 9 of 2024Week 13 of 2024Week 17 of 2024Week 21 of 2024Week 25 of 2024Week 29 of 2024Week 33 of 2024Week 37 of 2024Week 41 of 2024Week 45 of 2024Week 49 of 2024Week 1 of 2025Week 5 of 2025Week 9 of 2025Week 13 of 2025Week 17 of 2025Week 21 of 2025Week 25 of 2025Week 29 of 2025Week 33 of 2025Week 37 of 2025

                            Age Group

                            Skip Data Table
                            Data Table Download Data (CSV)
                            Skipped data table.

                            Additional information about emergency department visits for flu for current and past seasons:‎‎‎

                            Surveillance Methods | Emergency Department Visits for COVID-19, flu, and RSV
                            Hospitalization surveillance

                            FluSurv-Net


                            The Influenza Hospitalization Surveillance Network (FluSurv-NET) conducts population-based surveillance for laboratory-confirmed influenza-related hospitalizations in select counties in 14 states and represents approximately 9% of the U.S. population. FluSurv-NET hospitalization data are preliminary. Patients admitted for laboratory-confirmed influenza-related hospitalization after April 30, 2025, will not be included in FluSurv-NET for the 2024-2025 season. Data on patients admitted through April 30, 2025, will continue to be updated on FluView Interactive as additional information is received.

                            Additional FluSurv-NET hospitalization surveillance information for current and past seasons and additional age groups:

                            Surveillance Methods | FluView Interactive: Rates by Age, Sex, and Race/Ethnicity or Data on Patient Characteristics | RESP-NET Interactive

                            National Healthcare Safety Network (NHSN) Hospital Respiratory Data


                            Hospitals report to NHSN the weekly number of patients with laboratory-confirmed influenza who were admitted to the hospital. Nationally, during Week 37, 932 (0.3 per 100,000 population) laboratory-confirmed influenza-associated hospitalizations were reported. When examining rates by age, the highest hospital admission rate per 100,000 population was among those 65 years and older (0.8), followed by those 50-64 years and 0-4 years (both 0.3).

                            Additional NHSN Hospital Respiratory Data information:

                            Surveillance Methods | Additional Data | FluView Interactive
                            Mortality surveillance

                            National Center for Health Statistics (NCHS) Mortality Surveillance


                            Based on NCHS mortality surveillance data available on September 18, 2025, 0.03% of the deaths that occurred during the week ending September 13, 2025 (Week 37) were due to influenza. The data presented are preliminary and may change as more data are received and processed.

                            Additional pneumonia, influenza and COVID-19 mortality surveillance information for current and past seasons:

                            Surveillance Methods | FluView Interactive Influenza-Associated Pediatric Mortality


                            No influenza-associated pediatric deaths occurring during the 2024-2025 season were reported to CDC during Week 37. A total of 280 influenza-associated pediatric deaths occurring during the 2024-2025 season have been reported to CDC. This is the highest number of pediatric deaths reported in any non-pandemic influenza season since the condition became reportable in 2004.

                            Among children who were eligible for influenza vaccination and with known vaccine status, 90% of reported pediatric deaths this season (compared to 82% during the 2023-2024 season) have occurred in children who were not fully vaccinated against influenza.

                            Additional pediatric mortality surveillance information for current and past seasons:

                            Surveillance Methods | FluView Interactive
                            All data in this report are preliminary and may change as more reports are received.

                            A description of the CDC influenza surveillance system, including methodology and detailed descriptions of each data component, is available on the surveillance methods page.1

                            Additional information on the current and previous influenza seasons for each surveillance component are available on FluView Interactive.

                            Additional National and International Influenza Surveillance Information

                            Additional surveillance information


                            FluView Interactive: FluView includes enhanced web-based interactive applications that can provide dynamic visuals of the influenza data collected and analyzed by CDC. These FluView Interactive applications allow people to create customized, visual interpretations of influenza data, as well as make comparisons across flu seasons, regions, age groups and a variety of other demographics.

                            National Institute for Occupational Safety and Health: Monthly surveillance data on the prevalence of health-related workplace absenteeism among full-time workers in the United States are available from NIOSH.

                            Comment


                            • #44
                              Weekly US Influenza Surveillance Report: Key Updates for Week 38, ending September 20, 2025

                              For Everyone
                              Sept. 26, 2025

                              Key points


                              Seasonal influenza activity is low.
                              U.S. virologic surveillance

                              Clinical Laboratories


                              The results of tests performed by clinical laboratories nationwide are summarized below. Data from clinical laboratories (the percentage of specimens tested that are positive for influenza) are used to monitor whether influenza activity is increasing or decreasing. Nationally, during Week 38, the percentage of respiratory specimens testing positive for influenza virus in clinical laboratories was 0.4%.
                              No. of specimens tested 45,194 4,136,992
                              No. of positive specimens (%) 160 (0.4%) 490,225 (11.8%)
                              Positive specimens by type
                              Influenza A 140 (87.5%) 435,551 (88.8%)
                              Influenza B 20 (12.5%) 54,674 (11.2%)
                              Public Health Laboratories


                              The results of tests performed by public health laboratories nationwide are summarized below. Data from public health laboratories are used to monitor the proportion of circulating viruses that belong to each influenza virus type/subtype/lineage. Viruses known to be associated with recent live attenuated influenza vaccine (LAIV) receipt or found upon further testing to be a vaccine virus are not included as they are not circulating influenza viruses.
                              No. of specimens tested 371 158,016
                              No. of positive specimens 27 100,436
                              Positive specimens by type/subtype
                              Influenza A 25 (92.6%) 94,434 (94.0%)
                              Subtyping Performed 15 (60.0%) 84,916 (89.9%)
                              (H1N1)pdm09 6 (40.0%) 45,079 (53.1%)
                              H3N2 9 (60.0%) 39,758 (46.8%)
                              H3N2v 0 0
                              H5 0 79 (0.1%)
                              Subtyping not performed 10 (40.0%) 9,518 (10.1%)
                              Influenza B 2 (7.4%) 6,002 (6.0%)
                              Lineage testing performed 0 3,354 (55.9%)
                              Yamagata lineage 0 0
                              Victoria lineage 0 3,354 (100%)
                              Lineage not performed 2 (100%) 2,648 (44.1%)
                              *These data reflect specimens tested, and the number determined to be positive for influenza viruses at the public health labs (specimens tested is not the same as cases). The data do not reflect specimens tested only at CDC and could include more than one specimen tested per person. The guidance for avian influenza A(H5) virus testing recommends testing both a conjunctival and respiratory swab for people with conjunctivitis which has resulted in more specimens testing positive for avian influenza A(H5) virus than the number of human A(H5) cases. For more information on the number of people infected with avian influenza A(H5) viruses, please visit the "How CDC is monitoring influenza data among people to better understand the current avian influenza A (H5N1) situation"

                              When an influenza virus that normally circulates in swine (but not people) is detected in a person, it is called a "variant" influenza virus. Most human infections with variant influenza viruses occur following exposure to swine, but human-to-human transmission can occur. It is important to note that in most cases, variant influenza viruses have not shown the ability to spread easily and sustainably from human-to-human.



                              *This graph reflects the number of specimens tested and the number determined to be positive for influenza viruses at the public health lab (specimens tested is not the same as cases). It does not reflect specimens tested only at CDC and could include more than one specimen tested per person. Specimens tested as part of routine influenza surveillance as well as those tested as part of targeted testing for people exposed to avian influenza A(H5) are included.

                              Additional virologic surveillance information for current and past seasons:

                              Surveillance Methods | FluView Interactive: National, Regional, and State Data or Age Data

                              Novel Influenza A Virus Infections


                              No confirmed human infections with influenza A(H5) virus were reported to CDC this week. To date, human-to-human transmission of avian influenza A(H5) virus (H5 bird flu) has not been identified in the United States.

                              The CSTE position statement, which includes updated case definitions for confirmed, probable, and suspected cases is available at http://www.cste.org/resource/resmgr/...nfluenza_A.pdf.

                              An up-to-date human case summary during the current outbreak by state and exposure source is available at www.cdc.gov/bird-flu/situation-summary/index.html.

                              Information about avian influenza is available at https://www.cdc.gov/flu/avianflu/index.htm.

                              A(H5N1) virus interim recommendations for Prevention, Monitoring, and Public Health Investigations are available at https://www.cdc.gov/bird-flu/prevent...endations.html.

                              The latest case reports on avian influenza outbreaks in wild birds, commercial poultry, backyard or hobbyist flocks, and mammals in the United States are available from the USDA at https://www.aphis.usda.gov/h5n1-hpai#detections-hpai.

                              Additional information regarding human infections with novel influenza A viruses:

                              Surveillance Methods | FluView Interactive
                              Outpatient and Emergency Department Illness Surveillance

                              Outpatient Respiratory Illness Visits


                              The U.S. Outpatient Influenza-like Illness Surveillance Network (ILINet) monitors outpatient visits for respiratory illness referred to as influenza-like illness [ILI (fever plus cough or sore throat)], not laboratory-confirmed influenza, and may capture respiratory illness visits due to infection with any pathogen that can present with similar symptoms, including influenza, SARS-CoV-2, and RSV. Therefore, it is important to evaluate syndromic surveillance data, including that from ILINet, in the context of other sources of surveillance data to obtain a complete and accurate picture of influenza, SARS-CoV-2, and other respiratory virus activity.

                              Nationally, during Week 38, 1.7% of patient visits reported through ILINet were due to respiratory illness that included fever plus a cough or sore throat, also referred to as ILI. Multiple respiratory viruses are co-circulating, and the current relative contribution of influenza virus infection to ILI varies by location.

                              Outpatient Respiratory Illness Visits by Age Group


                              More than 70% of ILINet participants provide both the number of patient visits for respiratory illness and the total number of patient visits for the week broken out by age group. Data from this subset of providers are used to calculate the percentages of patient visits for respiratory illness by age group.

                              During Week 38, the percentage of visits for respiratory illness reported in ILINet was 5.1% among those 0-4 years, 2.4% among those 5-24 years, 1.4% among those 25-49 years, 0.9% among those 50-64 years, and 0.7% among those 65 years and older.

                              Outpatient Respiratory Illness Activity Map


                              Data collected in ILINet are used to produce a measure of ILI activity* by state/jurisdiction and Core Based Statistical Areas (CBSA).
                              Week 38
                              (Week ending
                              Sep. 20, 2025)
                              Week 37
                              (Week ending
                              Sep. 13, 2025)
                              Week 38
                              (Week ending
                              Sep. 20, 2025)
                              Week 37
                              (Week ending
                              Sep. 13, 2025)
                              Very High 0 0 0 0
                              High 0 0 0 2
                              Moderate 0 0 3 4
                              Low 1 0 24 26
                              Minimal 54 55 657 659
                              Insufficient Data 0 0 245 238
                              *Data collected in ILINet may disproportionally represent certain populations within a jurisdiction or CBSA, and therefore, may not accurately depict the full picture of influenza activity for the entire jurisdiction or CBSA. Differences in the data presented here by CDC and independently by some health departments likely represent differing levels of data completeness with data presented by the health department likely being the more complete.

                              Additional information about medically attended visits for ILI for current and past seasons:

                              Surveillance Methods | FluView Interactive: National, Regional, and State Data or ILI Activity Map

                              National Syndromic Surveillance System (NSSP)


                              The overall percentage of emergency department (ED) visits with a discharge diagnosis of influenza reported in NSSP was 0.1% during Week 38. The percentage of visits was 0.3% among those 0-4 years and 5-17 years, and 0.1% among those 18-64 years and 65 years and older. RegionNationalRegion 1Region 2Region 3Region 4Region 5Region 6Region 7Region 8Region 9Region 10
                              Season2023-2024 & 2024-20252022-2023 Skip Over Chart Container
                              2.0%4.0%6.0%8.0%10.0%12.0%14.0%16.0%Percent of Emergency Department Visits for InfluenzaWeek 42 of 2023Week 46 of 2023Week 50 of 2023Week 2 of 2024Week 6 of 2024Week 10 of 2024Week 14 of 2024Week 18 of 2024Week 22 of 2024Week 26 of 2024Week 30 of 2024Week 34 of 2024Week 38 of 2024Week 42 of 2024Week 46 of 2024Week 50 of 2024Week 2 of 2025Week 6 of 2025Week 10 of 2025Week 14 of 2025Week 18 of 2025Week 22 of 2025Week 26 of 2025Week 30 of 2025Week 34 of 2025Week 38 of 2025 Age Group

                              Skip Data Table
                              Data Table Download Data (CSV)
                              Skipped data table.

                              Additional information about emergency department visits for flu for current and past seasons:‎‎‎

                              Surveillance Methods | Emergency Department Visits for COVID-19, flu, and RSV
                              Hospitalization surveillance

                              FluSurv-Net


                              The Influenza Hospitalization Surveillance Network (FluSurv-NET) conducts population-based surveillance for laboratory-confirmed influenza-related hospitalizations in select counties in 14 states and represents approximately 9% of the U.S. population. FluSurv-NET hospitalization data are preliminary. Patients admitted for laboratory-confirmed influenza-related hospitalization after April 30, 2025, will not be included in FluSurv-NET for the 2024-2025 season. Data on patients admitted through April 30, 2025, will continue to be updated on FluView Interactive as additional information is received.

                              Additional FluSurv-NET hospitalization surveillance information for current and past seasons and additional age groups:

                              Surveillance Methods | FluView Interactive: Rates by Age, Sex, and Race/Ethnicity or Data on Patient Characteristics | RESP-NET Interactive

                              National Healthcare Safety Network (NHSN) Hospital Respiratory Data


                              Hospitals report to NHSN the weekly number of patients with laboratory-confirmed influenza who were admitted to the hospital. Nationally, during Week 38, 837 (0.3 per 100,000 population) laboratory-confirmed influenza-associated hospitalizations were reported. When examining rates by age, the highest hospital admission rate per 100,000 population was among those 65 years and older (0.8), followed by those 0-4 years and 50-64 years (0.2).

                              Additional NHSN Hospital Respiratory Data information:

                              Surveillance Methods | Additional Data | FluView Interactive
                              Mortality surveillance

                              National Center for Health Statistics (NCHS) Mortality Surveillance


                              Based on NCHS mortality surveillance data available on September 25, 2025, 0.03% of the deaths that occurred during the week ending September 20, 2025 (Week 38) were due to influenza. The data presented are preliminary and may change as more data are received and processed.

                              Additional pneumonia, influenza and COVID-19 mortality surveillance information for current and past seasons:

                              Surveillance Methods | FluView Interactive

                              Influenza-Associated Pediatric Mortality


                              One influenza-associated pediatric death that occurred during Week 50 (the week ending December 14, 2024) of the 2024-2025 season was reported to CDC during Week 38. A total of 281 influenza-associated pediatric deaths occurring during the 2024-2025 season have been reported to CDC. This is the highest number of pediatric deaths reported in any non-pandemic influenza season since the condition became reportable in 2004.

                              Among children who were eligible for influenza vaccination and with known vaccine status, 89% of reported pediatric deaths this season (compared to 82% during the 2023-2024 season) have occurred in children who were not fully vaccinated against influenza.

                              Additional pediatric mortality surveillance information for current and past seasons:

                              Surveillance Methods | FluView Interactive
                              All data in this report are preliminary and may change as more reports are received.

                              A description of the CDC influenza surveillance system, including methodology and detailed descriptions of each data component, is available on the surveillance methods page.1

                              Additional information on the current and previous influenza seasons for each surveillance component are available on FluView Interactive.

                              Additional National and International Influenza Surveillance Information

                              Additional surveillance information


                              FluView Interactive: FluView includes enhanced web-based interactive applications that can provide dynamic visuals of the influenza data collected and analyzed by CDC. These FluView Interactive applications allow people to create customized, visual interpretations of influenza data, as well as make comparisons across flu seasons, regions, age groups and a variety of other demographics.

                              National Institute for Occupational Safety and Health: Monthly surveillance data on the prevalence of health-related workplace absenteeism among full-time workers in the United States are available from NIOSH.

                              Comment

                              Working...
                              X